[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 279
1. Dixit A, Robertson JH, Mudan SS, Akle C: Appendiceal mucocoeles and pseudomyxoma peritonei. World J Gastroenterol; 2007 Apr 28;13(16):2381-4
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal mucocoeles and pseudomyxoma peritonei.
  • The most important aetiology, from a surgical perspective, is either mucinous cystadenoma or cystadenocarcinoma.
  • In the latter, a spontaneous or iatrogenic rupture of the mucocoele can lead to mucinous intraperitoneal ascites, a syndrome known as pseudomyxoma peritonei.
  • We report two cases and subsequently discuss the clinical presentation of mucocoeles, their association with pseudomyxoma peritonei and an optimal management of both conditions.
  • [MeSH-major] Cecal Neoplasms / diagnosis. Cystadenoma, Mucinous / diagnosis. Mucocele / diagnosis. Peritoneal Neoplasms / diagnosis. Pseudomyxoma Peritonei / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2000 Oct;87(10):1414-8 [11044169.001]
  • [Cites] J Am Coll Surg. 2006 Apr;202(4):680-4 [16571440.001]
  • [Cites] Clin Radiol. 2002 Jul;57(7):608-13 [12096860.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2002 Oct;12(5):367-70 [12409708.001]
  • [Cites] Radiographics. 2003 May-Jun;23(3):645-62 [12740466.001]
  • [Cites] J Comput Assist Tomogr. 2003 May-Jun;27(3):297-306 [12794590.001]
  • [Cites] Arch Surg. 2003 Jun;138(6):585-9; discussion 589-90 [12799327.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1089-103 [12883241.001]
  • [Cites] J Ultrasound Med. 2004 Jan;23(1):117-21; quiz 122-3 [14756359.001]
  • [Cites] Br J Surg. 2004 Mar;91(3):304-11 [14991630.001]
  • [Cites] Acta Chir Scand. 1973;139(4):392-400 [4718184.001]
  • [Cites] Cancer. 1973 Dec;32(6):1525-41 [4757938.001]
  • [Cites] Am J Gastroenterol. 1992 Jun;87(6):787-9 [1590322.001]
  • [Cites] Surg Gynecol Obstet. 1992 Nov;175(5):401-4 [1440166.001]
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):441-7 [8211593.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):112-9 [8129481.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):299-306 [7795991.001]
  • [Cites] Adv Surg. 1996;30:233-80 [8960339.001]
  • [Cites] Clin Radiol. 1998 Feb;53(2):149-50 [9502094.001]
  • [Cites] Abdom Imaging. 1998 May-Jun;23(3):292-6 [9569300.001]
  • [Cites] Surg Endosc. 1998 Sep;12(9):1177-9 [9716778.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 1999 Apr;9(2):159-63 [10235354.001]
  • [Cites] Gut. 1963 Jun;4:158-68 [13954206.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):300-8 [15650641.001]
  • [Cites] Ann Chir. 2005 Feb;130(2):63-9 [15737316.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1372-9 [15909071.001]
  • [Cites] Adv Anat Pathol. 2005 Nov;12(6):291-311 [16330927.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):69-76 [16389186.001]
  • [Cites] Int Surg. 2001 Oct-Dec;86(4):259-62 [12056473.001]
  • (PMID = 17511043.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4147153
  •  go-up   go-down


2. Liu L, Sun L, Wang J, Ji G, Chen B, Zhang H: Ovarian cystadenocarcinoma and pseudomyxoma peritonei. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cystadenocarcinoma and pseudomyxoma peritonei.
  • Localised pseudomyxoma peritonei associated with adenocarcinoma of the right ovary was diagnosed.
  • CONCLUSIONS: Pseudomyxoma peritonei may occur in patients with ovarian cystadenocarcinoma.
  • In such patients, the ovary should be investigated and transvaginal ultrasound can be carefully performed in cases of ruptured mucoceles and localised pseudomyxoma peritonei.
  • [MeSH-major] Cystadenocarcinoma / pathology. Cystadenocarcinoma / surgery. Mucocele / secondary. Mucocele / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / pathology. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Diagnostic Imaging. Female. Humans. Lymph Node Excision. Middle Aged

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2003 Jun;138(6):585-9; discussion 589-90 [12799327.001]
  • [Cites] Tech Coloproctol. 2004 Aug;8(2):109-12 [15309649.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):916-20 [18248391.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):35-9 [16767904.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1270-6 [16838392.001]
  • [Cites] Surg Today. 1995;25(8):745-9 [8520171.001]
  • [Cites] Clin Radiol. 2002 Jul;57(7):608-13 [12096860.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Apr;15(2):73-7 [12708714.001]
  • [Cites] BMC Gastroenterol. 2006;6:32 [17074081.001]
  • [Cites] Arch Gynecol Obstet. 2008 Sep;278(3):265-7 [18293005.001]
  • [Cites] Abdom Imaging. 2000 May-Jun;25(3):311-6 [10823458.001]
  • (PMID = 22753161.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3029120
  •  go-up   go-down


3. Gupta S, Singh G, Gupta A, Singh H, Arya AK, Shrotriya D, Kumar A: Pseudomyxoma peritonei: An uncommon tumor. Indian J Med Paediatr Oncol; 2010 Apr;31(2):58-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei: An uncommon tumor.
  • Pseudomyxoma peritonei is a poorly understood and uncommon tumor that is known for its production of mucin in the abdominal cavity and mucinous implants, diffusely involving the peritoneal surfaces.
  • On work-up, she was diagnosed as a case of Pseudomyxoma peritonei (with residual disease).
  • She received chemotherapy in the form of oral capecitabine for residual disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 1999 Jul;11(4):312-7 [10416885.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):458-63 [11260116.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):239-43 [11373099.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):85-91 [11443613.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1518-20 [15084625.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):682-8 [14511618.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):393-8 [15070599.001]
  • [Cites] Ann Surg Oncol. 2002 Dec;9(10):961-7 [12464587.001]
  • (PMID = 21209766.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2970936
  • [Keywords] NOTNLM ; Oral capecitabine / Pseudomyxoma peritonei
  •  go-up   go-down


Advertisement
4. Sugarbaker PH: New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol; 2006 Jan;7(1):69-76
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
  • Appendiceal mucinous neoplasms sometimes present with peritoneal dissemination, which was previously a lethal condition with a median survival of about 3 years.
  • Now, visible disease tends to be removed through visceral resections and peritonectomy.
  • To avoid entrapment of tumour cells at operative sites and to destroy small residual mucinous tumour nodules, cytoreductive surgery is combined with intraperitoneal chemotherapy with mitomycin at 42 degrees C.
  • If the mucinous neoplasm is minimally invasive and cytoreduction complete, these treatments result in a 20-year survival of 70%.
  • In the absence of a phase III study, this new combined treatment should be regarded as the standard of care for epithelial appendiceal neoplasms and pseudomyxoma peritonei syndrome.
  • [MeSH-major] Appendiceal Neoplasms / drug therapy. Appendiceal Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16389186.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Number-of-references] 38
  •  go-up   go-down


5. Pai RK, Longacre TA: Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification. Adv Anat Pathol; 2005 Nov;12(6):291-311
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification.
  • Pseudomyxoma peritonei is an overused and underspecified condition that has garnered much attention in the historic literature.
  • In recent years, this condition has been convincingly linked to appendiceal mucinous neoplasms, yet there has been insufficient attention to the histologic characteristics, classification, and differential diagnostic considerations of these neoplasms when encountered by the surgical pathologist.
  • This review provides a coherent approach to the diagnosis and classification of appendiceal mucinous tumors and the peritoneal implants associated with the pseudomyxoma peritonei syndrome with emphasis on differential diagnostic considerations and recommendations for the final pathology report.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Appendiceal Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330927.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


6. Beyrouti MI, Beyrouti R, Frikha F, Ben Amar M, Abid M, Ben Ameur H, Ben Salah K, Guirat A, Boujelben S: [Peritoneal gelatinous ascites]. Presse Med; 2007 Jul-Aug;36(7-8):1141-7
Genetic Alliance. consumer health - Gelatinous Ascites.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal gelatinous ascites].
  • [Transliterated title] La maladie gélatineuse du péritoine.
  • Pseudomyxoma peritonei or gelatinous ascites is a rare clinical entity, and its pathogenesis remains obscure.
  • It most often follows a mucinous tumor of the appendix.
  • Preoperative diagnosis is facilitated by modern imaging techniques.
  • Effusion in the lesser peritoneal cavity suggests this diagnosis.
  • Magnetic resonance imaging, by showing the gelatinous ascites, their septa and the scalloping of liver and spleen, can strengthen the probability of the diagnosis.
  • [MeSH-major] Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / diagnosis. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Appendectomy. Biopsy, Needle. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Hyperthermia, Induced. Laparotomy. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / therapy. Paracentesis. Preoperative Care. Rare Diseases. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603922.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


7. Lin HL, Chen JT, Liu YF, Cho DY: Sciatica caused by pseudomyxoma peritonei. J Chin Med Assoc; 2009 Jan;72(1):39-41
MedlinePlus Health Information. consumer health - Sciatica.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sciatica caused by pseudomyxoma peritonei.
  • Bilateral ovarian borderline mucinous cystic tumor with pseudomyxoma peritonei (PMP) was diagnosed, and the sciatica was improved dramatically after subsequent abdominal debulking surgery.
  • Although rare, neural compression caused by PMP and intra-abdominal masses needs to be considered in the differential diagnosis of sciatica.
  • [MeSH-major] Pseudomyxoma Peritonei / complications. Sciatica / etiology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19181596.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


8. Zappa L, Godwin TA, Sugarbaker PH: Tailgut cyst, an unusual cause of pseudomyxoma peritonei. Tumori; 2009 Jul-Aug;95(4):514-7
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailgut cyst, an unusual cause of pseudomyxoma peritonei.
  • METHODS: The clinical information on a single patient with pseudomyxoma peritonei associated with a tailgut cyst was reviewed and a literature review of the subject performed.
  • RESULTS: In this patient there was malignant degeneration of a tailgut cyst localized to the pelvis.
  • Twenty months later a local recurrence in the pelvis and pseudomyxoma peritonei widely distributed in the abdomen were successfully treated by cytoreductive surgery and perioperative chemotherapy.
  • CONCLUSION; Tailgut cyst may, if resected with tumor spillage, result in pseudomyxoma peritonei.
  • Our treatment--which has maintained a disease-free status for one year--was cytoreductive surgery plus perioperative chemotherapy.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Hamartoma / complications. Neoplasms, Multiple Primary / complications. Peritoneal Neoplasms / complications. Pseudomyxoma Peritonei / complications. Rectal Diseases / complications

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856666.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Bradley RF, Stewart JH 4th, Russell GB, Levine EA, Geisinger KR: Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol; 2006 May;30(5):551-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review.
  • Pseudomyxoma peritonei is a clinical term for gelatinous ascites, usually secondary to an appendiceal tumor.
  • The pathologic classification of pseudomyxoma peritonei and its associated appendiceal tumors has been plagued with controversy and confusing terminology.
  • In an effort to clarify this, we reviewed the pathology of 101 patients, all treated at our institution from 1993 to 2005, with pseudomyxoma peritonei of appendiceal origin.
  • This is the largest pathologic series solely devoted to appendiceal neoplasia with gelatinous ascites.
  • The cases were assigned, according to previously published criteria, to the categories of disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), or PMCA with intermediate (well differentiated) features (PMCA-I), with the exception that any case with a signet-ring cell component was considered as PMCA and not PMCA-I.
  • After reviewing our data and the literature, mucinous carcinoma peritonei-low grade was applied to the low-grade histology of pseudomyxoma peritonei, including those cases referred to by some as DPAM in the same category as PMCA-I.
  • Cases that are moderately differentiated to poorly differentiated are classified as mucinous carcinoma peritonei-high grade.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Peritoneal Neoplasms / classification. Peritoneal Neoplasms / secondary. Pseudomyxoma Peritonei / classification. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2006 Nov;30(11):1483-4; author reply 1484-5 [17063093.001]
  • (PMID = 16699309.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA131482
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Ohe C, Sakaida N, Yanagimoto Y, Toyokawa H, Satoi S, Kwon AH, Tadokoro C, Takasu K, Uemura Y: A case of splenic low-grade mucinous cystadenocarcinoma resulting in pseudomyxoma peritonei. Med Mol Morphol; 2010 Dec;43(4):235-40
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of splenic low-grade mucinous cystadenocarcinoma resulting in pseudomyxoma peritonei.
  • Primary splenic mucinous cystadenocarcinoma (MCCa) is extremely rare, and only six cases appear to have been reported previously.
  • We present herein a case of primary splenic MCCa resulting in pseudomyxoma peritonei (PMP).
  • The abdominal cavity was filled with a large amount of gelatinous ascites, with the appearance of PMP.
  • On the cut surface, multiple cysts containing mucinous material were found within and outside the spleen.
  • Microscopically, splenic parenchyma was occupied by large mucinous pools focally lined with mucinous epithelial cells and mesothelial cell-like cells, which were considered benign.
  • Although most PMP cases are known to be caused by low-grade mucinous appendiceal tumor, the present case represents the first report of a splenic MCCa resulting in PMP.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology. Splenic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21267701.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Friedrich M, Poleska W, Baltzer J, Salehin D: Treatment of pseudomyxoma peritonei by intraoperative and intraperitoneal chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of pseudomyxoma peritonei by intraoperative and intraperitoneal chemotherapy.
  • : e16540 Background: Pseudomyxoma peritonei occurs mostly in conjunction with the type of intestinal mucinous borderline tumour and is characterized by building up a lot of mucus pour of cells.
  • The most common tumor is the pseudomyxoma peritoneii with mucinous borderline tumours of the ovaries or with mucinous tumours of the appendix, normally without showing a rupture of the ovarian tumour pre- or intraoperatively.
  • The diagnosis of pseudomyxoma peritonei is mainly difficult and guidelines for the treatment are unknown.
  • METHODS: In the period from 1991 to 2008, 52 patients with pseudomyxoma peritonei were treated by tumour debulking and intraoperative and intraperitoneal chemotherapy with Mitoxantron (40 mg in 300 ml of NaCl over 72 hours).
  • There were the following histologies: mucinous cystadenoma of the ovary n = 29, mucinous cystadenoma of the appendix n = 10, mucinous cystadenocarcinoma n = 13.
  • CONCLUSIONS: The instillation of mitoxantron intraperitoneally and intraoperatively is an effective and safe therapy without any side effects after maximal tumour debulking of pseudomyxoma peritoneii.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960827.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Glehen O, Elias D, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Association Française de Chirurgie: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from digestive or primitive origin: A multi-institutional study of 1,290 patients. J Clin Oncol; 2009 May 20;27(15_suppl):4102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from digestive or primitive origin: A multi-institutional study of 1,290 patients.
  • : 4102 Background: Peritoneal carcinomatosis (PC) from non-gynecologic malignancies has long been regarded a terminal disease with a short median survival.
  • The principal etiologies of PC were colorectal adenocarcinoma (N=523), pseudomyxoma peritonei (N=301), gastric adenocarcinoma (N=159), peritoneal mesothelioma (N=88), and appendiceal adenocarcinoma (N=50).
  • The overall median survival was 34 months: 30 months for colorectal PC, not reached for pseudomyxoma peritonei, 9 months for gastric PC, 41 months for peritoneal mesothelioma, and 77 months for PC from appendiceal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961196.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Mukherjee S, Weir C, Hammer H: Presumed fungal retinitis associated with pseudomyxoma peritonei. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presumed fungal retinitis associated with pseudomyxoma peritonei.
  • Pseudomyxoma peritonei is a rare malignant growth characterised by the progressive accumulation of mucus-secreting (mucinous) tumour cells within the abdomen and pelvis.1 No previous ophthalmic associations have been reported with this condition.
  • He was treated appropriately and recovered his vision well.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Probl Surg. 2008 Aug;45(8):527-75 [18590843.001]
  • [Cites] Clin Infect Dis. 2000 Apr;30(4):662-78 [10770728.001]
  • (PMID = 21686849.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028183
  •  go-up   go-down


14. Hsu KH, Chou CY, Chang YC: Intraperitoneal hyperthermia in the management of pseudomyxoma peritonei. Hepatogastroenterology; 2007 Jan-Feb;54(73):47-52
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal hyperthermia in the management of pseudomyxoma peritonei.
  • BACKGROUND/AIMS: Pseudomyxoma peritonei is a rare disease characterized by diffuse intraperitoneal mucinous tumor and massive mucinous ascites.
  • METHODOLOGY: From 1995 to 2002, 8 patients with pathologically confirmed pseudomyxoma peritonei were studied.
  • RESULTS: The appendix was the origin of pseudomyxoma peritonei in 6 patients, the ovary in 1 patient, and the fallopian tube in another.
  • The pathologic diagnosis was mucinous adenocarcinoma in 4 patients, mucinous cystadenocarcinoma in 3, and mucinous cystadenoma in 1.
  • CONCLUSIONS: Surgical debulking followed by 46 C normal saline intraperitoneal hyperthermia resulted in a 5-year survival of 49% with low morbidity and no mortality for the treatment of pseudomyxoma peritonei.
  • We concluded that this is an easy, safe, and efficacious treatment for patients with this rare disease.
  • [MeSH-major] Hyperthermia, Induced. Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystadenocarcinoma, Mucinous / pathology. Female. Humans. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419229.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Li B, Pan WD, Qin MW: [Computed tomography appearance of pseudomyxoma peritonei]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Oct;30(5):603-6
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Computed tomography appearance of pseudomyxoma peritonei].
  • OBJECTIVE: To study the characteristics of computed tomography (CT) appearance in pseudomyxoma peritonei.
  • METHODS: CT findings were retrospectively reviewed in 7 patients with surgically and pathologically confirmed pseudomyxoma peritonei.
  • RESULTS: All patients had large-volume ascites with heterogeneous density, hepatic and splenic scallopings, and peritoneal and omental infiltration on CT.
  • Other findings included calcification, septa, mucinous masses, pleural effusion, and ureteral dilation.
  • CONCLUSION: CT appearance in pseudomyxoma peritonei has certain characteristics, which should be carefully recognized by radiologists during examinations.
  • [MeSH-major] Pseudomyxoma Peritonei / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024395.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


16. Cabanas J, Gomes da Silva R, Goldstein P, Verghese M, Sugarbaker PH: Recurrence of pseudomyxoma peritonei within the inguinal canal. Tumori; 2005 Nov-Dec;91(6):481-6
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of pseudomyxoma peritonei within the inguinal canal.
  • AIM AND BACKGROUND: Tumor appearing in an inguinal hernia sac indicates widespread carcinomatosis with ascites.
  • A new onset hernia is a common clinical presentation of pseudomyxoma peritonei syndrome arising in an appendiceal mucinous tumor.
  • Recurrence of pseudomyxoma peritonei within the inguinal region was previously reported in only a single patient.
  • We present five patients with a recurrence of pseudomyxoma peritonei tumor nodules in the inguinal region following cytoreductive surgery and attempt to understand the etiology of this treatment failure.
  • METHODS AND STUDY DESIGN: From a database of 910 patients with mucinous appendiceal tumors with peritoneal dissemination who had definitive treatment, five patients who had disease recurrence within the inguinal region were identified.
  • RESULTS: Five patients with ages ranging 39 to 67 years had a mucinous tumor in the inguinal region as a recurrence after a previous cytoreductive surgery combined with perioperative intraperitoneal chemotherapy.
  • All these patients were made disease-free by the reoperative surgery with a sacrifice of the testicle in four.
  • None have evidence of a recurrence of an inguinal hernia despite the lack of formal repair.
  • This may be more problematic in patients who have had prior surgery with mucoid fluid in a hernia as the presenting sign of pseudomyxoma peritonei.
  • [MeSH-major] Adenocarcinoma, Mucinous. Hernia, Inguinal / etiology. Inguinal Canal. Neoplasm Recurrence, Local. Peritoneal Neoplasms. Pseudomyxoma Peritonei

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457146.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Gatalica Z, Loggie B: COX-2 expression in pseudomyxoma peritonei. Cancer Lett; 2006 Nov 28;244(1):86-90
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COX-2 expression in pseudomyxoma peritonei.
  • COX-2 expression was studied using an immunohistochemical method in 75 patients with pseudomyxoma peritonei (PMP).
  • Twenty-five patients presented with disseminated peritoneal adenomucinosis (DPAM) and 50 with peritoneal mucinous carcinomatosis (PMCA).
  • COX-2 was expressed in neoplastic mucinous epithelium of 30 cases (40%): 20 in PMCA (40%), 10 in DPAM (40%).
  • Weak COX-2 expression was also noted in four of five patients with appendiceal mucinous neoplasms without peritoneal dissemination.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Membrane Proteins / metabolism. Peritoneal Neoplasms / enzymology. Pseudomyxoma Peritonei / enzymology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Appendiceal Neoplasms / diagnosis. Appendiceal Neoplasms / enzymology. Appendiceal Neoplasms / secondary. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / enzymology. Cystadenoma, Mucinous / secondary. Endothelial Cells / enzymology. Endothelial Cells / pathology. Epithelium / enzymology. Epithelium / pathology. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Prospective Studies. Receptor, ErbB-2 / metabolism. Stromal Cells / enzymology. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16427185.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


18. Kotani Y, Shiota M, Umemoto M, Tobiume T, Koike E, Shimaoka M, Takahashi Y, Kanemura K, Ishizu A, Hoshiai H: Laparoscopic mucin removal in patients with pseudomyxoma peritonei. JSLS; 2009 Apr-Jun;13(2):203-6
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic mucin removal in patients with pseudomyxoma peritonei.
  • BACKGROUND AND OBJECTIVES: Pseudomyxoma peritonei results from ovarian and appendiceal mucinous tumors.
  • Pseudomyxoma peritonei is generally associated with a poor prognosis.
  • In a recent Mayo Clinic report, the 5-year survival rate for this disease was 53% and the 10-year survival rate was 32%, while the Memorial Sloan-Kettering Cancer Center reported 5- and 10-year survival rates of 75% and 10%.
  • METHODS AND RESULTS: In this report, we describe 4 patients with a laparoscopically confirmed recurrence of pseudomyxoma peritonei who subsequently underwent repeated laparoscopic mucin removal.
  • CONCLUSION: Because laparoscopic surgery can be performed frequently, it appears that laparoscopic surgery, a minimally invasive procedure, greatly improves the quality of life of patients with pseudomyxoma peritonei.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2002 May;183(5):529-32 [12034386.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):542-6 [17929098.001]
  • [Cites] Rom J Gastroenterol. 2002 Sep;11(3):213-8 [12368941.001]
  • [Cites] Aust N Z J Surg. 1975 Aug;45(3):277-9 [126682.001]
  • [Cites] Cancer. 1975 Nov;36(5):1834-7 [1192367.001]
  • [Cites] Cancer Res. 1980 Feb;40(2):256-60 [6766084.001]
  • [Cites] Radiology. 1984 Nov;153(2):507-10 [6385111.001]
  • [Cites] Eur J Radiol. 1989 May;9(2):115-8 [2663488.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):396-401 [1319813.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(3):213-7 [8508878.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):112-9 [8129481.001]
  • [Cites] Am Surg. 1995 Mar;61(3):265-70 [7887544.001]
  • [Cites] Adv Surg. 1996;30:233-80 [8960339.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 1999 Jun;9(3):299-303 [10414551.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):300-8 [15650641.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):544-50 [16919104.001]
  • [CommentIn] JSLS. 2010 Jan-Mar;14(1):152; author reply 152-3 [20529543.001]
  • (PMID = 19660216.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  • [Other-IDs] NLM/ PMC3015933
  •  go-up   go-down


19. Järvinen P, Lepistö A: Clinical presentation of pseudomyxoma peritonei. Scand J Surg; 2010;99(4):213-6
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation of pseudomyxoma peritonei.
  • BACKGROUND AND AIMS: We analysed the clinical symptoms and signs of pseudomyxoma peritonei (PMP), a rare syndrome affecting one to two persons per million annually.
  • Presumably, patients with PMP would benefit from early diagnosis.
  • MATERIAL AND METHODS: We performed a retrospective chart review of a consecutive series of 82 PMP cases at the Helsinki University Central Hospital from June 1984 to September 2009.
  • The subsequent more common chief complaints were acute abdomen with 21%, increased abdominal girth with 17%, coincidental diagnosis with 13%, other reasons with 13% and newly onset hernia with 12% of the cases.
  • Of the 82 initial operations, 23 (28%) were performed with a suspicion or diagnosis of PMP.
  • Diagnostics of PMP is challenging due to the mimicking nature of the disease.
  • [MeSH-major] Diagnostic Errors. Peritoneal Neoplasms / complications. Peritoneal Neoplasms / diagnosis. Pseudomyxoma Peritonei / complications. Pseudomyxoma Peritonei / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Diagnostic Imaging. Early Diagnosis. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Second-Look Surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21159590.001).
  • [ISSN] 1457-4969
  • [Journal-full-title] Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
  • [ISO-abbreviation] Scand J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Guo AT, Wei LX, Song X: [Histologic classification and prognostic implication of pseudomyxoma peritonei]. Zhonghua Bing Li Xue Za Zhi; 2007 Jul;36(7):474-9
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histologic classification and prognostic implication of pseudomyxoma peritonei].
  • OBJECTIVE: To clarify the various diagnostic connotations of pseudomyxoma peritonei (PMP) and to study their prognostic implications.
  • The cases were histologically classified into 3 subcategories: disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), and PMCA with intermediate or discordant features (PMCA-I/D).
  • The mean age of the patients at the time of diagnosis was 50.3 years (age range = 22 to 76 years).
  • On the other hand, the presence of appendiceal tumor, parenchymal invasion of abdominal viscera, cellularity, architecture, nuclear atypia and mitotic activity of the peritoneal lesion significantly correlated with survival.
  • Peritoneal lesions with higher cellularity, conspicuous nuclear atypia and higher mitotic activity are associated with a lower survival rate.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Appendiceal Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845762.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Sugiyama K, Ito N: Mucinous cystadenocarcinoma of the urachus associated with pseudomyxoma peritonei with emphasis on MR findings. Magn Reson Med Sci; 2009;8(2):85-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenocarcinoma of the urachus associated with pseudomyxoma peritonei with emphasis on MR findings.
  • Urachal mucinous cystadenocarcinoma associated with pseudomyxoma peritonei is extremely rare; only 11 cases are reported.
  • We describe the characteristic imaging findings of this disorder and correlate imaging features by computed tomography, magnetic resonance imaging, and ultrasonography with operative findings and histopathologic specimens.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / diagnosis. Magnetic Resonance Imaging / methods. Neoplasms, Multiple Primary / diagnosis. Peritoneal Neoplasms / diagnosis. Pseudomyxoma Peritonei / diagnosis. Urachus
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Ultrasonography

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571501.001).
  • [ISSN] 1347-3182
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


22. Sugarbaker PH, Verghese M, Yan TD, Brun E: Management of mucinous urachal neoplasm presenting as pseudomyxoma peritonei. Tumori; 2008 Sep-Oct;94(5):732-6
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of mucinous urachal neoplasm presenting as pseudomyxoma peritonei.
  • BACKGROUND: Mucinous neoplasms of the urachus are rare malignancies so that the physicians' index of suspicion for a timely and accurate diagnosis is low.
  • Also, this disease may present with a wide variety of symptoms and signs.
  • METHODS: Two patients with pseudomyxoma peritonei as the initial presentation of urachal mucinous adenocarcinoma were treated successfully.
  • The medical literature regarding treatment options for this manifestation of the disease was searched.
  • RESULTS: Two patients with large volume of pseudomyxoma peritonei originating in a mucinous urachal neoplasm were treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • Our first patient required two reoperations to palliate the accumulation of gross mucinous ascites.
  • She died 11 years after diagnosis with progression of mucinous adenocarcinoma resulting in starvation.
  • The patient is currently without evidence of disease and has a normal quality of life.
  • Seven prior manuscripts that report a single case of pseudomyxoma peritonei were reviewed to explore the full range of treatment options and survival for this rare condition.
  • CONCLUSION: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy may be a new treatment option for mucinous urachal neoplasms presenting with pseudomyxoma peritonei.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Adenocarcinoma, Mucinous / diagnosis. Peritoneal Neoplasms / etiology. Pseudomyxoma Peritonei / etiology. Urachus / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Middle Aged. Reoperation. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112949.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 14
  •  go-up   go-down


23. Järvinen P, Järvinen HJ, Lepistö A: Survival of patients with pseudomyxoma peritonei treated by serial debulking. Colorectal Dis; 2010 Sep;12(9):868-72
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients with pseudomyxoma peritonei treated by serial debulking.
  • AIM: We evaluated the outcome of patients with pseudomyxoma peritonei (PMP) after traditional debulking.
  • PMP is a clinical condition characterized by disseminated intraperitoneal mucinous tumours often accompanied by mucinous ascites derived usually from an appendiceal neoplasm.
  • However, four patients (12%) seemed to have achieved long-term disease-free survival of more than 5 years.
  • [MeSH-major] Palliative Care / methods. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2010 Sep;12(9):872-3 [20718839.001]
  • (PMID = 19519686.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Okada N, Ishibashi K, Nakada H, Miyazaki T, Sobajima J, Gonda T, Ishida H: [Five cases of pseudomyxoma peritonei underwent abdominal lavage and administering CDDP]. Gan To Kagaku Ryoho; 2007 Nov;34(12):1955-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Five cases of pseudomyxoma peritonei underwent abdominal lavage and administering CDDP].
  • We examined five cases of pseudomyxoma peritonei with treatments of cytoreduction surgery, abdominal lavage and intraperiotoneal administration of cisplatin (CDDP).
  • Histological types contained one case of well differentiated adenocarcinoma and four cases of signet ring cell carcinoma.
  • There were no cases of collected ascites within one year, except one case that we could not follow.
  • [MeSH-major] Cisplatin / therapeutic use. Peritoneal Lavage. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219863.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Chatti S, Ben Brahim E, Sidhom O, Ben Othman M, Zidi Y, Salah MB, Sassi S, Regaya SM, Touinsi H: [Comparative study of appendical mucocela and pseudomyxoma peritonei. About 25 cases]. Tunis Med; 2007 Dec;85(12):1044-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative study of appendical mucocela and pseudomyxoma peritonei. About 25 cases].
  • [Transliterated title] Etude comparative des mucoceles simples et des mucoceles compliques de pseudomyxome. A propos de 25 observations.
  • AIM: to study the clinicopathological features of the different types of appendical mucocele and to compare them with those of pseudomyxoma peritonei.
  • RESULTS: 9 retentionnal cysts, 13 mucinous cystadenomas, one serrated adenoma, one hyperplasia of the mucosa and one cystadenocarcinoma were diagnosed.
  • Five cystadenomas as well as the only case of cystadenocarcinoma were associated with pseudomyxoma peritonei.
  • Pseudomyxoma peritonei occurred 20 years later than in simple appendiceal mucocèle and complicated 5 cases of cystadenoma with low grade dysplasia and 1 case of cystadenocarcinoma.
  • CONCLUSION: Preoperative diagnosis of appendical mucocele and pseudomyxoma peritonei should be made on scannographic features in order to assess the adequate surgical management.
  • [MeSH-major] Appendiceal Neoplasms / complications. Appendix. Cystadenocarcinoma / complications. Cystadenoma / complications. Mucocele / complications. Peritoneal Neoplasms / complications. Pseudomyxoma Peritonei / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Cystadenocarcinoma, Mucinous / complications. Cystadenocarcinoma, Mucinous / surgery. Cystadenoma, Mucinous / complications. Cystadenoma, Mucinous / surgery. Female. Humans. Male. Middle Aged. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19170385.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


26. Brueggen C, Baird G, Meisheid A: Pseudomyxoma peritonei syndrome of appendiceal origin: an overview. Clin J Oncol Nurs; 2007 Aug;11(4):525-32
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei syndrome of appendiceal origin: an overview.
  • Pseudomyxoma peritonei (PMP) syndrome is an uncommon, slowly progressive condition that usually arises from perforation of an adenoma in the appendix.
  • PMP syndrome is characterized by mucin accumulation in the peritoneal cavity.
  • Mucinous implants are found on all peritoneal surfaces and the omentum.
  • PMP syndrome rarely metastasizes outside the abdominal cavity but remains a fatal illness as the space in the abdomen and pelvis required for normal function of the gastrointestinal tract becomes filled with copious amounts of the mucinous tumor.
  • [MeSH-major] Appendiceal Neoplasms / diagnosis. Appendiceal Neoplasms / therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / diagnosis. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Aftercare. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Drug Administration Schedule. Humans. Incidence. Infusions, Parenteral. Oncology Nursing / organization & administration. Palliative Care. Patient Care Planning. Peritoneal Lavage. Posture. Rare Diseases. Syndrome. Tomography, X-Ray Computed. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17723965.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 44
  •  go-up   go-down


27. Samet I, Cormier B, Mowlawi H, Philippe A, Arbion F, Fétissof F: [Endometrial and endocervical lesions associated with pseudomyxoma peritonei: a case report]. Ann Pathol; 2009 Jun;29(3):233-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrial and endocervical lesions associated with pseudomyxoma peritonei: a case report].
  • [Transliterated title] Lésions endométriale et endocervicale associées au pseudomyxome péritonéal : à propos d'une observation.
  • The association of a pseudomyxoma peritonei with a mucinous tumor of the appendix and/or the ovary is regularly reported in the literature.
  • We report the case of a 57-year-old patient, with pseudomyxoma peritonei associated with a low-grade mucinous neoplasia of appendix and both ovaries.
  • The endocervical and endometrial lesions might represent an implantation of mucinous epithelium from appendix, emphasizing the capacity of this epithelium to implant at a distance from the original lesion.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Appendiceal Neoplasms / complications. Cervix Uteri / pathology. Endometrium / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / complications. Pseudomyxoma Peritonei / etiology
  • [MeSH-minor] Appendectomy. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Epithelial Cells / pathology. Female. Humans. Hysterectomy. Metaplasia. Middle Aged. Neoplasm Invasiveness. Ovariectomy


28. Misdraji J: Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med; 2010 Jun;134(6):864-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal mucinous neoplasms: controversial issues.
  • Low grade appendiceal mucinous neoplasms can spread to the peritoneum as pseudomyxoma peritonei even though they are not obviously invasive in the appendix.
  • During the past several decades, several problematic issues surrounding this enigmatic tumor have been debated in the literature, including appropriate nomenclature for the appendiceal tumors and their peritoneal metastases.
  • In this article, the most contentious issues in the area of appendiceal mucinous tumors are examined.
  • First, the classification systems that have been proposed for these tumors are compared in the context of whether the appendiceal mucinous tumors are ruptured adenomas or invasive carcinomas.
  • The controversy about the nature of pseudomyxoma peritonei and its classification systems is discussed in the following section.
  • A brief discussion follows that examines the issue of localized pseudomyxoma peritonei and its clinical significance.
  • Next reviewed is the largely resolved controversy about whether ovarian mucinous tumors in this setting are separate primaries or are metastases from the appendiceal tumor.
  • Finally, the controversy about the most effective treatment of patients with pseudomyxoma peritonei is discussed.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Appendiceal Neoplasms / diagnosis. Pseudomyxoma Peritonei / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / secondary. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524864.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


29. Song ZQ, Wang WZ, Lu XH, Ke MY, Sun XH, Cui QC: [The clinical and pathological characteristics and prognosis of pseudomyxoma peritonei]. Zhonghua Nei Ke Za Zhi; 2005 Dec;44(12):894-7
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical and pathological characteristics and prognosis of pseudomyxoma peritonei].
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment measures and prognosis of pseudomyxoma peritonei (PMP).
  • RESULTS: Thirty-three patients (twenty-two women, eleven men) have a median interval between onset and definite diagnosis of 12 months with an average age of 50.
  • A delay in diagnosis is common and many patients are labeled as other diseases (84.8%).
  • Gastrointestinal tumor markers, imaging and abdominal paracentesis are very important to the diagnosis.
  • [MeSH-major] Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / diagnosis. Pseudomyxoma Peritonei / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16409722.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Shah VB, Amonkar GP, Deshpande JR, Bhalekar H: Mucinous adenocarcinoma of the renal pelvis with pseudomyxoma peritonei. Indian J Pathol Microbiol; 2008 Oct-Dec;51(4):536-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of the renal pelvis with pseudomyxoma peritonei.
  • Mucinous adenocarcinoma of the renal pelvis is an extremely rare tumor with very few case reports in literature.
  • Pseudomyxoma peritonei is an uncommon condition characterized by the presence of mucinous gelatinous material in the peritoneal cavity.
  • It occurs secondary to primary mucinous neoplasms of particularly the appendix and the ovary.
  • We present a case of a 35-year-old female who had a history of dull aching pain in the right flank since one and a half years.
  • Grossly, the entire kidney was converted into a cystic mass measuring 15x15x12 cm containing gelatinous mucinous material weighing 1 kg.
  • Thus, a diagnosis of mucinous adenocarcinoma of the renal pelvis leading to pseudomyxoma peritonei was made.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Neoplasms, Multiple Primary / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19008588.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


31. Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg; 2006 Oct;93(10):1270-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
  • BACKGROUND: Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) has been used to treat pseudomyxoma peritonei.
  • The aim of this prospective study was to evaluate survival outcome and treatment-related prognostic markers in patients who underwent CRS and PIC for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
  • CONCLUSION: CRS combined with PIC was associated with improved survival in patients with less extensive previous surgery and diffuse peritoneal adenomucinosis histopathological type.
  • [MeSH-major] Adenocarcinoma, Mucinous / mortality. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / mortality. Peritoneal Neoplasms / mortality. Pseudomyxoma Peritonei / mortality

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838392.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


32. Manan AZ, Raja MH, Namukangula R, Benayan AA: Appendiceal pseudomyxoma peritonei in a pregnant woman. Saudi Med J; 2010 May;31(5):572-4
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal pseudomyxoma peritonei in a pregnant woman.
  • We report an unusual case of pseudomyxoma peritonei (PMP) in a 41-year-old full-term pregnant woman.
  • Cesarean section was carried out, and the abdomen was found to contain an appendiceal mucinous tumor with large volume PMP.
  • This case illustrates the incidental nature of the disease and its occurrence in a pregnant woman with no clinical features during the antenatal period.
  • Pseudomyxoma peritonei is commonly discovered during surgery for other conditions, and a high index of suspicion is required to make a diagnosis.
  • Diagnostic modalities such as ultrasound, CT, and MRI can provide some evidence for PMP, but the definitive diagnosis is only made laparoscopically or by exploratory laparotomy.
  • [MeSH-major] Appendiceal Neoplasms / surgery. Peritoneal Neoplasms / surgery. Pregnancy Complications, Neoplastic / surgery. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Adult. Cesarean Section. Diagnosis, Differential. Female. Humans. Pregnancy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464051.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 12
  •  go-up   go-down


33. McKenney JK, Longacre TA: Low-grade mucinous epithelial neoplasm (intestinal type) arising in a mature sacrococcygeal teratoma with late recurrence as pseudomyxoma peritonei. Hum Pathol; 2008 Apr;39(4):629-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade mucinous epithelial neoplasm (intestinal type) arising in a mature sacrococcygeal teratoma with late recurrence as pseudomyxoma peritonei.
  • Mucinous epithelial neoplasms associated with mature teratomas are well described in the gonads, and some examples have presented with clinical pseudomyxoma peritonei.
  • The association between pseudomyxoma peritonei and an extragonadal teratoma is limited to a single case report.
  • We describe a mature teratoma in the sacrococcygeal region associated with an intestinal-type mucinous epithelial neoplasm that recurred with a disseminated intraperitoneal low-grade mucinous epithelial neoplasm and mucinous ascites.
  • To our knowledge, this is the first reported case of a mature teratoma-associated mucinous epithelial neoplasm from any anatomical site with documented late recurrence as pseudomyxoma peritonei.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Intestinal Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Multiple Primary / diagnosis. Peritoneal Neoplasms / diagnosis. Pseudomyxoma Peritonei / diagnosis. Sacrococcygeal Region. Teratoma / diagnosis


34. Shinohara T, Misawa K, Sano H, Okawa Y, Takada A: Pseudomyxoma peritonei due to mucinous cystadenocarcinoma in situ of the urachus presenting as an inguinal hernia. Int J Clin Oncol; 2006 Oct;11(5):416-9
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei due to mucinous cystadenocarcinoma in situ of the urachus presenting as an inguinal hernia.
  • Pseudomyxoma peritonei is generally caused by appendiceal and ovarian tumors.
  • We describe herein the second reported case of pseudomyxoma peritonei due to mucinous cystadenocarcinoma of the urachus.
  • During herniorrhaphy, we found a large amount of gelatinous mucinous material in the indirect-hernia sac and made a diagnosis of pseudomyxoma peritonei on cytological grounds.
  • At re-operation, the origin of the pseudomyxoma peritonei proved to be a ruptured urachal cyst.
  • In addition, we removed as much of the gelatinous material as possible.
  • On histological examination, a unilocular cyst was found to consist of noninvasive mucinous adenocarcinoma.
  • We succeeded in removing the rest of the mucinous material by postoperative intraperitoneal lavage with dextran solution, and have observed no evidence of recurrence for 7 years since the operation.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / diagnosis. Hernia, Inguinal / etiology. Neoplasms, Multiple Primary. Peritoneal Neoplasms / diagnosis. Pseudomyxoma Peritonei / diagnosis. Urachus
  • [MeSH-minor] Humans. Male. Middle Aged. Peritoneal Lavage. Treatment Outcome. Urachal Cyst / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058142.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Chen CF, Huang CJ, Kang WY, Hsieh JS: Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4). World J Surg Oncol; 2008;6:118
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4).
  • BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare condition characterized by mucinous tumors, disseminated intra-peritoneal implants, and mucinous ascites.
  • So far its diagnosis remains challenging to most clinicians.
  • A large amount of ascites was identified by abdominal computed tomography (CT) scan.
  • Paracentesis showed the appearance of sticky mucinous ascites.
  • He underwent laparotomy under the impression of pseudomyxoma peritonei.
  • There was a lot of mucinous ascites, one appendiceal tumor and multiple peritoneal implants disseminated from the subphrenic space to the recto-vesicle pouch.
  • Pseudomyxoma Peritonei caused by mucinous adenocarcinoma of appendiceal origin, was confirmed by histopathology.
  • CONCLUSION: This case report emphasizes the possible new role of systemic chemotherapy in the treatment of patients with this rare clinical syndrome.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Pseudomyxoma Peritonei / drug therapy

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Res. 1996;81:105-19 [8834579.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):1-9 [8986525.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1849-55 [10362811.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1372-9 [15909071.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):69-76 [16389186.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):551-9 [16699309.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):104-9 [17197972.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):493-9 [17103067.001]
  • [Cites] Cancer Treat Rev. 2007 Apr;33(2):138-45 [17182192.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Br J Surg. 2000 Oct;87(10):1414-8 [11044169.001]
  • [Cites] J Surg Oncol. 2000 Dec;75(4):270-4 [11135270.001]
  • [Cites] Gynecol Obstet Invest. 2001;51(2):73-80 [11223697.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):239-43 [11373099.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8 [12911716.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):682-8 [14511618.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(4):411-4 [15285293.001]
  • [Cites] Cancer. 1975 Nov;36(5):1834-7 [1192367.001]
  • [Cites] Gynecol Oncol. 1985 Oct;22(2):257-9 [4054721.001]
  • [Cites] Am J Surg Pathol. 1991 May;15(5):415-29 [2035736.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):396-401 [1319813.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):591-603 [8179074.001]
  • [Cites] Hum Pathol. 1995 May;26(5):509-24 [7750935.001]
  • [Cites] Adv Surg. 1996;30:233-80 [8960339.001]
  • (PMID = 19014441.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2615010
  •  go-up   go-down


36. Bryant J, Clegg AJ, Sidhu MK, Brodin H, Royle P, Davidson P: Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg; 2005 Feb;92(2):153-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei.
  • BACKGROUND: Pseudomyxoma peritonei, a rare progressive disease process within the peritoneum, is characterized by an abundance of mucinous fluid; if left untreated, the condition is fatal.
  • The aim of this article is to assess the clinical effectiveness and costs of the Sugarbaker procedure for pseudomyxoma peritonei.
  • Survival after operation was approximately 95 per cent at 2 years and 60-68 per cent at 10 years, with 41-52 per cent of patients having no evidence of disease at the end of follow-up.
  • CONCLUSION: Evidence of the effectiveness of the Sugarbaker procedure for pseudomyxoma peritonei is limited in quantity and quality, but suggests there may be some benefit for patients.
  • [MeSH-major] Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685704.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 17
  •  go-up   go-down


37. Satani M, Oomae N, Tomita A, Shimbo M, Yonemura Y: [Blood transfusion therapy for massive hemorrhage associated with scheduled peritonectomy for pseudomyxoma peritonei and peritoneal dissemination]. Masui; 2009 Apr;58(4):432-7
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Blood transfusion therapy for massive hemorrhage associated with scheduled peritonectomy for pseudomyxoma peritonei and peritoneal dissemination].
  • We investigated whether the component therapy was useful for surgical patients undergoing the scheduled peritonectomy for pseudomyxoma peritonei or peritoneal dissemination.
  • CONCLUSIONS: If the hemorrhage of more than the circulation volume is suspected before the operation, early transfusion therapy seems to provide good effect for coagulation in scheduled peritonectomy of pseudomyxoma peritonei or peritoneal dissemination.
  • [MeSH-major] Blood Component Transfusion. Blood Loss, Surgical. Peritoneal Neoplasms / surgery. Peritoneum / surgery. Plasma. Pseudomyxoma Peritonei / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19364003.001).
  • [ISSN] 0021-4892
  • [Journal-full-title] Masui. The Japanese journal of anesthesiology
  • [ISO-abbreviation] Masui
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Murphy EM, Sexton R, Moran BJ: Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum; 2007 Jan;50(1):37-42
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm.
  • Occult rupture with features of pseudomyxoma peritonei may be encountered.
  • We report the operative findings, pathologic assessment, and early outcomes in 123 consecutive patients with a perforated appendiceal neoplasm presenting as pseudomyxoma peritonei.
  • METHODS: From March 1994 to March 2004, 292 patients were referred to a peritoneal malignancy surgical treatment center.
  • RESULTS: In total, 123 patients (52 males; 41 percent) underwent laparotomy for a perforated appendiceal malignancy presenting as pseudomyxoma peritonei.
  • Kaplan-Meier analysis of the 83 patients who had complete tumor removal predicted 75 percent disease-free survival at five years.
  • CONCLUSIONS: A perforated appendiceal epithelial tumor most frequently presents as pseudomyxoma peritonei.
  • This treatment strategy, involving surgery and intraperitoneal chemotherapy, can result in good outcomes in this rare and otherwise fatal disease.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Gastroenterol Hepatol. 2007 Sep;4(9):490-1 [17667901.001]
  • (PMID = 17115339.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


39. Güner Z, Schmidt U, Dahlke MH, Schlitt HJ, Klempnauer J, Piso P: Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Int J Colorectal Dis; 2005 Mar;20(2):155-60
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.
  • BACKGROUND AND AIMS: Surgical improvement can be achieved in selected patients with pseudomyxoma peritonei (PMP) by major cytoreductive surgery and intraperitoneal chemotherapy (IPEC).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Digestive System Surgical Procedures / methods. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503065.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


40. Senthil M, Harrison LE: Simultaneous bicavitary hyperthermic chemoperfusion in the management of pseudomyxoma peritonei with synchronous pleural extension. Arch Surg; 2009 Oct;144(10):970-2
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous bicavitary hyperthermic chemoperfusion in the management of pseudomyxoma peritonei with synchronous pleural extension.
  • Extra-abdominal spread of pseudomyxoma peritonei (PMP) is a rare event, but extension of the tumor beyond the abdomen into the pleural cavity has been reported.
  • During the abdominal cytoreductive surgery in a patient with known history of PMP, extensive disease under the right hemidiaphragm was noted, requiring partial diaphragmatic resection.
  • Once the pleural space was entered, separate mucinous deposits on the pleural surface of the diaphragm and lung surface were observed.
  • The diaphragmatic defect was left open during the hyperthermic chemoperfusion to treat both the pleural and peritoneal surfaces.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Hyperthermia, Induced. Neoplasms, Multiple Primary / therapy. Peritoneal Neoplasms / therapy. Pleural Neoplasms / therapy. Pseudomyxoma Peritonei / therapy

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19841367.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


41. Lepistö A, Osterlund P, Järvinen HJ: [Treatment of pseudomyxoma peritonei is developing]. Duodecim; 2010;126(14):1693-9
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pseudomyxoma peritonei is developing].
  • In pseudomyxoma peritonei a mucinous tumor of the appendix spreads into the abdominal cavity.
  • The symptoms were previously relieved by repeated resections of the tumor mass, whereby even the most benign form of the disease progressed slowly.
  • A method has now emerged in which radical-aimed surgery is combined with intraperitoneal lavage with a warmed solution of a cytotoxic agent.
  • [MeSH-major] Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Appendix / pathology. Combined Modality Therapy. Disease Progression. Humans. Neoplasm Invasiveness. Therapeutic Irrigation / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20804088.001).
  • [ISSN] 0012-7183
  • [Journal-full-title] Duodecim; lääketieteellinen aikakauskirja
  • [ISO-abbreviation] Duodecim
  • [Language] fin
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Finland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 22
  •  go-up   go-down


42. Zappa L, Sugarbaker PH: Mesenteric cyst: report of a case-resulting in pseudomyxoma peritonei. Tumori; 2010 Mar-Apr;96(2):332-5
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenteric cyst: report of a case-resulting in pseudomyxoma peritonei.
  • A mesenteric cyst has not previously been recorded as the cause of pseudomyxoma peritonei.
  • METHODS: A patient who developed widespread mucinous intraperitoneal tumor as a result of a ruptured mesenteric cyst is reported.
  • A literature review of the clinical features, diagnosis, treatment, and prognosis of the mesenteric cyst is presented.
  • Her recovery was uneventful and she remains well two years after treatment.
  • CONCLUSION: Mesenteric cyst is a rare cause of pseudomyxoma peritonei.
  • The definite treatment of a ruptured neoplastic mesenteric cyst can, by analogy, be compared to the treatment for pseudomyxoma peritonei of appendiceal origin.
  • [MeSH-major] Mesenteric Cyst / complications. Peritoneal Neoplasms / etiology. Pseudomyxoma Peritonei / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20572595.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


43. Chua TC, Yan TD, Yap ZL, Horton MD, Fermanis GG, Morris DL: Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei. J Surg Oncol; 2009 Apr 1;99(5):292-5
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei.
  • BACKGROUND: Pleural dissemination of pseudomyxoma peritonei (PMP) is considered an advanced/terminal disease.
  • Only one patient has died 38 months since treatment from abdominal complication of this disease with no evidence of thoracic disease.
  • Long-term disease-free survival can be achieved from this treatment for which no other potentially curative therapy has been described.
  • [MeSH-major] Hyperthermia, Induced / methods. Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Follow-Up Studies. Humans. Intraoperative Period. Length of Stay. Male. Middle Aged. Neoplasm Recurrence, Local. Reoperation. Thoracotomy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180588.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Geisinger KR, Levine EA, Shen P, Bradley RF: Pleuropulmonary involvement in pseudomyxoma peritonei: morphologic assessment and literature review. Am J Clin Pathol; 2007 Jan;127(1):135-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleuropulmonary involvement in pseudomyxoma peritonei: morphologic assessment and literature review.
  • Intrathoracic spread in patients with pseudomyxoma peritonei (PP) is rare.
  • In that study, we suggested mucinous carcinoma peritonei (MCP) as the pathologic terminology for all cases of PP.
  • Of 5 patients, 3 had low-grade histologic features in the peritoneum; these showed variably proliferative, bland-appearing neoplastic cells arising from low-grade appendiceal mucinous neoplasms.
  • Pleural cytologic examination revealed high-grade adenocarcinoma cells singly, in small clusters, and in large spheres.
  • Although rare, mucinous neoplasms from PP may involve the thorax.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Lung Neoplasms / secondary. Peritoneal Neoplasms / pathology. Pleural Neoplasms / secondary. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145619.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


45. Narvekar S, Vijaykumar P, Shetty N, Srinivas M, Rao K: Successful pregnancy in a patient with pseudomyxoma peritonei following in-vitro fertilization using donor eggs. J Hum Reprod Sci; 2008 Jul;1(2):90-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful pregnancy in a patient with pseudomyxoma peritonei following in-vitro fertilization using donor eggs.
  • Pseudomyxoma peritonei is a rare, chronic relapsing disease with a guarded prognosis.
  • Here, we describe such a case of a young patient presenting with primary infertility, who conceived following in-vitro fertilization with donor egg and had a successful pregnancy outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2000 Oct;87(10):1414-8 [11044169.001]
  • [Cites] Gynecol Obstet Invest. 2001;51(2):73-80 [11223697.001]
  • [Cites] Postgrad Med J. 2002 Mar;78(917):170-2 [11884702.001]
  • [Cites] Fertil Steril. 2005 Oct;84(4):1017 [16213858.001]
  • [Cites] Fertil Steril. 1992 Aug;58(2):425-6 [1633914.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):970-3 [2430456.001]
  • [Cites] Gynecol Oncol. 1995 Dec;59(3):398-400 [8522263.001]
  • (PMID = 19562054.001).
  • [ISSN] 0974-1208
  • [Journal-full-title] Journal of human reproductive sciences
  • [ISO-abbreviation] J Hum Reprod Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2700666
  • [Keywords] NOTNLM ; Donor egg / in-vitro fertilization / mucinous cystadenoma / pregnancy / pseudomyxoma peritonei
  •  go-up   go-down


46. Fujitani K, Ogawa H, Takeda M, Hirao M, Yasui M, Kashiwazaki M, Ikenaga M, Miyazaki M, Mishima H, Nakamori S, Manoh M, Tsujinaka T: [A case report of pseudomyxoma peritonei demonstrating complete response after intensive therapy consisting of cytoreductive surgery and adjuvant chemotherapy with paclitaxel and S-1]. Gan To Kagaku Ryoho; 2008 Mar;35(3):523-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of pseudomyxoma peritonei demonstrating complete response after intensive therapy consisting of cytoreductive surgery and adjuvant chemotherapy with paclitaxel and S-1].
  • A 74-year-old male with diffuse gelatinous ascites underwent cytoreductive surgery including ileocecal resection and greater omentectomy.
  • Pathology revealed mucinous adenocarcinoma with low-grade malignancy originating in the appendix with disseminated peritoneal adenomucinosis, which was diagnostic of pseudomyxoma peritonei.
  • The patient tolerated the chemotherapy well, developing grade 1 anemia and grade 2 neutropenia plus elevation of total bilirubin.
  • A follow-up computed tomography (CT) scan revealed small ascites only in the right pelvis 8 months later after the initial operation, and complete disappearance of ascites 17 months later.
  • Two years later, the patient presented with ileus, and required adhesionlysis as well as partial resection of adhesive ileum.
  • No evidence of recurrent disease was confirmed intraoperatively as a second look.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Oxonic Acid / therapeutic use. Paclitaxel / therapeutic use. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery. Tegafur / therapeutic use

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347410.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


47. Cioppa T, Vaira M, Bing C, D'Amico S, Bruscino A, De Simone M: Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei. World J Gastroenterol; 2008 Nov 28;14(44):6817-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei.
  • AIM: To investigate the most important aspects of hyperthermic intraperitoneal chemotherapy (HIPEC) that has been accepted as the standard treatment for pseudomyxoma peritonei (PMP), with special regard to morbidity, overall survival (OS) and disease free survival (DFS) over 10 years.
  • Preoperative evaluation always included thoracic and abdominal CT scan to stage peritoneal disease and exclude distant metastases.
  • Risk factors for postoperative morbidity were considered to be gender, age, body surface, duration of surgery, Peritoneal Cancer Index (PCI) and tumor residual value (CC score).
  • [MeSH-major] Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / etiology. Proportional Hazards Models. Reoperation. Risk Assessment. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):526-34 [18043976.001]
  • [Cites] Dis Colon Rectum. 2000 Oct;43(10):1341-6; discussion 1347-8 [11052509.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):979-84 [11334722.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):71-6 [11443611.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jul;126(7):837-41 [12088454.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1160-5 [12209247.001]
  • [Cites] J Surg Oncol. 2003 Feb;82(2):138-40 [12561072.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):799-806 [12610177.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):508-13 [12794016.001]
  • [Cites] Br J Surg. 2003 Sep;90(9):1113-9 [12945079.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):219-28 [15050953.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):325-32 [15297169.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):790-6 [10622509.001]
  • [Cites] Ann Surg Oncol. 2003 Oct;10(8):863-9 [14527903.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] J Surg Oncol. 2004 Feb;85(2):61-7 [14755505.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):178-86 [14761921.001]
  • [Cites] Br J Surg. 2004 Mar;91(3):304-11 [14991630.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] Cancer Treat Res. 1996;81:63-74 [8834576.001]
  • [Cites] Cancer Treat Res. 1996;81:149-68 [8834582.001]
  • [Cites] Cancer Treat Res. 1996;82:359-74 [8849962.001]
  • [Cites] Adv Surg. 1996;30:233-80 [8960339.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):884-91 [9041149.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1849-55 [10362811.001]
  • [Cites] Am J Surg. 1999 Sep;178(3):256-62 [10527450.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):53-8 [15642426.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):18-22 [15612012.001]
  • [Cites] Ann Surg Oncol. 2005 Nov;12(11):910-8 [16177862.001]
  • [Cites] Ann Surg Oncol. 2006 May;13(5):635-44 [16523363.001]
  • [Cites] World J Surg. 2006 Nov;30(11):2033-40; discussion 2041-2 [17006608.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):41-4 [10861608.001]
  • (PMID = 19058307.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2773876
  •  go-up   go-down


48. Qu ZB, Liu LX: Management of pseudomyxoma peritonei. World J Gastroenterol; 2006 Oct 14;12(38):6124-7
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of pseudomyxoma peritonei.
  • Pseudomyxoma peritonei (PMP) is a rare disease.
  • It refers to a progressive disease process within the peritoneum which originates from the appendix or ovaries and is characterised by the production of copious amounts of mucinous fluid resulting in a "jelly belly".
  • The natural history of this disease has been drastically modified since the introduction of a new surgical approach defined as a peritonectomy procedure.
  • [MeSH-major] Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Humans. Hyperthermia, Induced. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Peritoneum / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1994 Feb;219(2):109-11 [8129480.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):703-27, xiii [14567026.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4560-7 [14673042.001]
  • [Cites] Health Technol Assess. 2004 Feb;8(7):iii, 1-54 [14960255.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):393-8 [15070599.001]
  • [Cites] Eur J Surg Suppl. 1991 May;(561):75-82 [1720053.001]
  • [Cites] Oncology. 1993 Sep-Oct;50(5):366-70 [8378032.001]
  • [Cites] Surg Today. 1993;23(12):1094-8 [8118126.001]
  • [Cites] Tumori. 1997 Jul-Aug;83(4):725-8 [9349309.001]
  • [Cites] Tumori. 1999 Jan-Feb;85(1):1-5 [10228488.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):53-8 [15642426.001]
  • [Cites] Ann Chir. 2005 Feb;130(2):63-9 [15737316.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):153-8 [15685704.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1372-9 [15909071.001]
  • [Cites] Pancreatology. 2005;5(4-5):470-4 [15983445.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):458-63 [11260116.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):239-43 [11373099.001]
  • [Cites] Tumori. 2001 May-Jun;87(3):120-6 [11504363.001]
  • [Cites] Br J Surg. 2002 Feb;89(2):208-12 [11856136.001]
  • [Cites] Eur J Surg Oncol. 2002 Feb;28(1):80-7 [11869020.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):492-9 [11900234.001]
  • [Cites] Tumori. 2002 Sep-Oct;88(5):370-5 [12487553.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):799-806 [12610177.001]
  • [Cites] Int J Hyperthermia. 2003 Mar-Apr;19(2):193-203 [12623641.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):54-5 [12903545.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):682-8 [14511618.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):585-603 [14567019.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi [14567020.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):741-53 [14567028.001]
  • (PMID = 17036382.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC4088104
  •  go-up   go-down


49. Abdu B, Hobgood D, Stallings S, Depasquale S: Incidental finding of pseudomyxoma peritonei at primary cesarean section. Am J Perinatol; 2009 Oct;26(9):633-5
MedlinePlus Health Information. consumer health - Cesarean Section.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental finding of pseudomyxoma peritonei at primary cesarean section.
  • When cancer is present, the most frequent histology is mucinous adenocarcinoma.
  • Neoplasms of the appendix that secrete mucin such as adenocarcinoma may rupture, leading to intraperitoneal seeding of the peritoneum and producing the clinical picture of pseudomyxoma peritonei (PMP).
  • PMP is characterized by mucin-producing neoplastic cells that have seeded the peritoneum from the ruptured viscous and continue to secrete copious amounts of gelatinous material that accumulates in the abdomen producing the characteristic "jelly belly."
  • Upon opening of the peritoneum, copious amounts of gelatinous, yellow-tinged mucoid material was noted.
  • Pathology showed well-differentiated mucinous adenocarcinoma of the appendix.
  • Early diagnosis of a potentially life-threatening disease requires that clinicians expand the differential diagnosis and consider the possibility of a malignant neoplasm presenting in the pregnant female.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Cesarean Section. Incidental Findings. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Thieme Medical Publishers.
  • (PMID = 19399708.001).
  • [ISSN] 1098-8785
  • [Journal-full-title] American journal of perinatology
  • [ISO-abbreviation] Am J Perinatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


50. Rojo Sebastián A, Fernández Morejón FJ, Bretcha Boix P, Farré Alegre J, Forteza Vila J, Brugarolas Masllorens A: Controversial origin of Pseudomyxoma peritonei. Clin Transl Oncol; 2006 Oct;8(10):767-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversial origin of Pseudomyxoma peritonei.
  • Pseudomyxoma peritonei describes the accumulation of mucinous material in the abdominal cavity.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Appendiceal Neoplasms / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / etiology. Pseudomyxoma Peritonei / etiology
  • [MeSH-minor] Aged. Appendix / pathology. Diagnosis, Differential. Female. Humans. Ovary / pathology. Peritoneum / pathology. Prognosis

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074679.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


51. De Simone M, Vaira M, Caponi A, Ciaccio B, Fiorentini G, Turrisi G, Ferri L, Buti G: Ten years experience in the treatment of pseudomyxoma peritonei by cytoreduction, peritonectomy and semi-closed hyperthermic antiblastic peritoneal perfusion. In Vivo; 2006 Nov-Dec;20(6A):725-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten years experience in the treatment of pseudomyxoma peritonei by cytoreduction, peritonectomy and semi-closed hyperthermic antiblastic peritoneal perfusion.
  • BACKGROUND: In the literature good results have been reported for the treatment of Pseudomyxoma peritonei (PMP) by cytoreduction, peritonectomy and hyperthermic antiblastic peritoneal perfusion (H.A.P.P.).
  • PATIENTS AND METHODS: Peritoneal perfusion has been performed with the original semiclosed tecnique after complete surgical cytoreduction in 188 patients affected by peritoneal carcinomatosis.
  • The results of the Kaplan-Meier 5- and 10-year survival analysis, were 94% and 82%, respectively, with a disease-free survival of 80% at 5 years and 70% at 10 years.
  • Thirty-nine patients (81.2%) had no evidence of disease at follow-up (range 1-120 months).
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / therapy. Peritoneum / surgery. Pseudomyxoma Peritonei / therapy

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203755.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


52. Ishibashi K, Sobajima J, Okada N, Ishizuka N, Yokoyama M, Mitsuhashi T, Miyazaki T, Nakada H, Gonda T, Ishida H: [A case of pseudomyxoma peritonei successfully treated with multidisciplinary treatment including modified FOLFOX6 regimen]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2047-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pseudomyxoma peritonei successfully treated with multidisciplinary treatment including modified FOLFOX6 regimen].
  • We report a case of pseudomyxoma peritonei caused by carcinoma of the appendix, which was successfully treated with multidisciplinary treatment including modified FOLFOX6 regimen.
  • A 45-year-old man was diagnosed as having peritoneal dissemination associated with cancer of the cecum or appendix.
  • Seven cycles of mFOLFOX6 treatment resulted in a marked decrease in ascites and serum levels of carcinoembryonic antigen and carbohydrate antigen 19-9.
  • At laparotomy, a diagnosis of pseudomyxoma peritonei caused by cancer of the appendix was made.
  • Intraperitoneal lavarge with 10,000 mL 5% glucose was performed after right hemicolectomy, omentectomy and removed of mucinous peritoneal nodules.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219894.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


53. Loungnarath R, Causeret S, Bossard N, Faheez M, Sayag-Beaujard AC, Brigand C, Gilly F, Glehen O: Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum; 2005 Jul;48(7):1372-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study.
  • PURPOSE: Pseudomyxoma peritonei is a rare disease.
  • METHOD: Twenty-seven patients with pseudomyxoma peritonei who were treated by cytoreductive surgery and intraperitoneal chemohyperthermia between 1997 and 2003 were identified from a prospective database.
  • Histologic examination demonstrated Grade 1, 2, and 3 disease in 8 (30 percent), 10 (37 percent), and 9 patients (33 percent), respectively.
  • The actuarial five-year survival was 100 percent for patients with Grade 1 disease, whereas actuarial one-, two-, three-, and five-year survival for Grades 2 and 3 were 100, 80, 64, and 32 percent, respectively (P = 0.008).
  • CONCLUSIONS: Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy is a feasible treatment for pseudomyxoma peritonei.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909071.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


54. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA: Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg; 2007 Jan;245(1):104-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
  • OBJECTIVE: To evaluate the survival of patients with pseudomyxoma peritonei (PMP) treated by cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC), and to identify factors with prognostic value.
  • SUMMARY BACKGROUND DATA: PMP is a clinical syndrome characterized by progressive intraperitoneal accumulation of mucous and mucinous implants, usually derived from a ruptured mucinous neoplasm of the appendix.
  • PMP was pathologically categorized into disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), and an intermediate subtype (PMCA-I).
  • The median disease-free interval was 25.6 months (95% confidence interval [CI], 14.8-43.6 months).
  • The 3-year and 5-year disease-free survival probability was 43.6% (95% CI, 34.4%-55.2%) and 37.4% (95% CI, 28.2%-49.5%), respectively.
  • The disease-specific 3-year and 5-year survival probability was 70.9% (95% CI, 62.0%-81.2%) and 59.5% (95% CI 48.7%-72.5%), respectively.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hyperthermia, Induced. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2005 Mar;20(2):155-60 [15503065.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1372-9 [15909071.001]
  • [Cites] Br J Surg. 2006 Jan;93(1):100-4 [16302177.001]
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):186-90 [16303281.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):393-8 [15070599.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(4):411-4 [15285293.001]
  • [Cites] Gastroenterology. 1986 Jan;90(1):202-5 [2998918.001]
  • [Cites] J Urol. 1988 Apr;139(4):821-2 [3352057.001]
  • [Cites] Can J Surg. 1989 May;32(3):164-70 [2713770.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):109-11 [8129480.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):112-9 [8129481.001]
  • [Cites] Obstet Gynecol. 1994 Jul;84(1):17-21 [8008316.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Hum Pathol. 1995 May;26(5):509-24 [7750935.001]
  • [Cites] Eur J Surg. 1995 May;161(5):355-60 [7662781.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] Adv Surg. 1996;30:233-80 [8960339.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1332-9 [9782010.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):300-8 [15650641.001]
  • [Cites] J Surg Oncol. 2004 Feb;85(2):61-7 [14755505.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] J Surg Oncol. 2000 Dec;75(4):270-4 [11135270.001]
  • [Cites] Eur J Surg Oncol. 2001 Feb;27(1):54-8 [11237493.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):239-43 [11373099.001]
  • [Cites] Cancer Treat Rev. 2001 Dec;27(6):365-74 [11908929.001]
  • [Cites] Gastroenterol Clin Biol. 2003 Apr;27(4):407-12 [12759682.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [CommentIn] Ann Surg. 2008 Mar;247(3):556-7 [18376211.001]
  • (PMID = 17197972.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC1867935
  •  go-up   go-down


55. Schmuck RB, Pietzner K, Buckendahl A, Schönlebe J, Sehouli J: Cervical manifestation of a borderline type ovarian cancer with pseudomyxoma peritonei - a case report. Anticancer Res; 2010 Jul;30(7):2991-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical manifestation of a borderline type ovarian cancer with pseudomyxoma peritonei - a case report.
  • Borderline tumours of the ovary (BOTs) are rare tumour entities that do not show any destructive or invasive growth in the majority of cases, even though they can display characteristics of malignant tumours The mucinous subtype can also originate from the appendix, and ovarian metastases can mimic primary ovarian BOTs, often accompanied by peritoneal manifestation in terms of pseudomyxoma peritonei.
  • This report describes a special case of BOT with a specific example of the complexity of the differential diagnosis of pseudomyxoma peritonei.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Ovarian Neoplasms / diagnosis. Pseudomyxoma Peritonei / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cervix Uteri / pathology. Diagnosis, Differential. Female. Humans. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / pathology. Neoplasm Invasiveness


56. Yan TD, Black D, Savady R, Sugarbaker PH: A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol; 2007 Feb;14(2):484-92
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei.
  • BACKGROUND: The efficacy of cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) for patients with pseudomyxoma peritonei (PMP) remains to be established.
  • Due to the rarity of this disease, a well-designed prospective multi-institutional study would be meaningful.
  • [MeSH-major] Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054002.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 51
  •  go-up   go-down


57. Gillion JF, Franco D, Chapuis O, Serpeau D, Convard JP, Jullès MC, Balaton A, Karkouche B, Capelle P, Parmentier T, Chollet JM, Thillois JM, Berthelot G: [Appendiceal mucoceles, pseudomyxoma peritonei and appendiceal mucinous neoplasms: update on the contribution of imaging to choice of surgical approach]. J Chir (Paris); 2009 Apr;146(2):150-66
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Appendiceal mucoceles, pseudomyxoma peritonei and appendiceal mucinous neoplasms: update on the contribution of imaging to choice of surgical approach].
  • [Transliterated title] Mucocèles appendiculaires, pseudomyxomes péritonéaux et tumeurs mucosécrétantes du carrefour iléocaecal: apport de l'imagerie dans la stratégie thérapeutique et le choix de la voie d'abord laparoscopique ou classique.
  • INTRODUCTION: The treatment of pseudomyxoma peritonei (PMPs) and appendiceal mucocele (AM) has changed radically.
  • Eleven patients had an intact AM, seven synchronous PMP (malignant appendiceal lesion in two of seven), six metachronous PMP (five with peritoneal mucinous carcinomatosis and one with diffuse peritoneal adenomucinosis) and three a ruptured AM but not PMP.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Appendiceal Neoplasms / radiography. Appendix / radiography. Mucocele / radiography. Peritoneal Neoplasms / radiography. Pseudomyxoma Peritonei / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Chir (Paris). 2009 Apr;146(2):167 [19540495.001]
  • (PMID = 19552906.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


58. Khalid K, Ahmed MS, Malik MS: Adenocarcinoma of urachal cyst associated with pseudomyxoma peritonei masquerading as abdominal tuberculosis: A case report and review of literature. Indian J Urol; 2008 Apr;24(2):258-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of urachal cyst associated with pseudomyxoma peritonei masquerading as abdominal tuberculosis: A case report and review of literature.
  • Exploratory laparotomy revealed a urachal cyst associated with pseudomyxoma peritonei (PMP).
  • Histopathology confirmed a moderately differentiated mucin secreting adenocarcinoma of urachal cyst associated with PMP.
  • The adenocarcinoma of urachal cyst associated with PMP is further reviewed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1954 Aug;72(2):217-21 [13184579.001]
  • [Cites] Pathol Int. 1997 Jul;47(7):502-5 [9234391.001]
  • [Cites] South Med J. 1971 Apr;64(4):497-8 [4324014.001]
  • [Cites] Acta Radiol. 2004 May;45(3):348-50 [15239434.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1091-3 [17021133.001]
  • (PMID = 19468408.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2684289
  • [Keywords] NOTNLM ; Adenocarcinoma / pseudomyxoma peritonei / urachal cyst
  •  go-up   go-down


59. Chua TC, Yan TD, Smigielski ME, Zhu KJ, Ng KM, Zhao J, Morris DL: Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol; 2009 Jul;16(7):1903-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution.
  • BACKGROUND: Cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) has been recognized as a treatment option for pseudomyxoma peritonei.
  • METHODS: Patients with pseudomyxoma peritonei underwent CRS and PIC, which was comprised of hyperthermic intraperitoneal chemotherapy (HIPEC) and/or early postoperative intraperitoneal chemotherapy (EPIC), according to a standardized treatment protocol in our institution.
  • Time period comparison was performed to study the effect of a learning curve.
  • Factors influencing survival include histopathological type of tumor, use of both HIPEC and EPIC, peritoneal cancer index, completeness of cytoreduction, and severe morbidity.
  • The results demonstrate a learning curve where patients with a higher peritoneal cancer index (PCI) were treated, reduced amount of blood products required, more patients undergoing HIPEC and the combined HIPEC and EPIC, more redo-procedures performed, and a longer progression-free survival.
  • CONCLUSIONS: This report demonstrates long-term survival outcomes, acceptable perioperative outcomes, and a learning curve associated with the treatment of patients with pseudomyxoma peritonei.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Pseudomyxoma Peritonei / mortality. Pseudomyxoma Peritonei / therapy

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387742.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


60. Heiskala K, Giles-Komar J, Heiskala M, Andersson LC: High expression of RELP (Reg IV) in neoplastic goblet cells of appendiceal mucinous cystadenoma and pseudomyxoma peritonei. Virchows Arch; 2006 Mar;448(3):295-300
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of RELP (Reg IV) in neoplastic goblet cells of appendiceal mucinous cystadenoma and pseudomyxoma peritonei.
  • By immunohistochemistry and in situ hybridization, we found a robust de novo expression of RELP in the neoplastic goblet cells of appendiceal mucinous cystadenomas and in the epithelial implants of pseudomyxoma peritonei (PMP).
  • Our findings indicate that RELP serves as a marker for appendiceal mucinous cystadenomas and PMP, and that RELP may contribute to the pathogenesis of these disorders.
  • [MeSH-major] Appendiceal Neoplasms / metabolism. Cystadenoma, Mucinous / metabolism. Goblet Cells / metabolism. Lectins, C-Type / metabolism. Pseudomyxoma Peritonei / metabolism

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323007.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / REG4 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


61. Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M: Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol; 2007 Aug;14(8):2300-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
  • BACKGROUND: Encouraging results have been recently reported in selected patients affected by pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • Baseline and serial marker measurements were prospectively collected and tested by multivariate analysis with respect to adequate cytoreduction, overall (OS) and progression-free (PFS) survival, along with the following variables: age, sex, performance status, prior surgical score, histological subtype, prior systemic chemotherapy, disease extent, completeness of cytoreduction.
  • [MeSH-major] Biomarkers, Tumor / blood. Hyperthermia, Induced. Peritoneal Neoplasms / blood. Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / blood. Pseudomyxoma Peritonei / therapy

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17510772.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Mucin-1; 0 / Receptors, Cell Surface; 0 / carcinoembryonic antigen binding protein, human; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


62. Saran RK, Majumdar K, Kaur S, Mishra PK, Gondal R: Organizing mucinous ascitis masquerading as pseudomyxoma peritonei: a process possibly caused by metaplasia but not neoplasia. J Surg Educ; 2008 May-Jun;65(3):221-4
MedlinePlus Health Information. consumer health - Appendicitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organizing mucinous ascitis masquerading as pseudomyxoma peritonei: a process possibly caused by metaplasia but not neoplasia.
  • Mucinous ascitis can be differentiated from the more ominous condition pseudomyxoma peritonei microscopically by the absence of epithelial cells amidst mucin pools in the former.
  • Herein we communicate a brief report of organizing mucinous ascitis in a 34-year-old woman, with recurrent abdominal pain localized to right iliac fossa.
  • Conservative management, followed by appendicectomy and enbloc removal of the surrounding mucinous adhesions, was performed.
  • There was an absence of morphologically well-defined, neoplastic epithelial cells in the mucinous pool, thus excluding the diagnosis of pseudomyxoma peritonei.
  • The localized mucinous ascitis possibly have originated from the mucinous metaplasia of the mesothelial lining cells of the peritoneum, secondary to recurrent attacks of appendicitis.
  • [MeSH-major] Appendicitis / pathology. Appendix / pathology. Ascitic Fluid / metabolism. Mucins / metabolism. Pseudomyxoma Peritonei / diagnosis
  • [MeSH-minor] Adult. Chronic Disease. Epithelium / pathology. Female. Humans. Immunohistochemistry. Metaplasia

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18571136.001).
  • [ISSN] 1931-7204
  • [Journal-full-title] Journal of surgical education
  • [ISO-abbreviation] J Surg Educ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


63. Lee JK, Song SH, Kim I, Lee KH, Kim BG, Kim JW, Kim YT, Park SY, Cha MS, Kang SB: Retrospective multicenter study of a clinicopathologic analysis of pseudomyxoma peritonei associated with ovarian tumors (KGOG 3005). Int J Gynecol Cancer; 2008 Sep-Oct;18(5):916-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective multicenter study of a clinicopathologic analysis of pseudomyxoma peritonei associated with ovarian tumors (KGOG 3005).
  • The purpose of this study is to assess clinicopathologic features of pseudomyxoma peritonei (PMP) that has ovarian pathology and its relationship with the prognosis.
  • The mean age at diagnosis was 53.7 years (range: 16-82 years).
  • There were 25 (71.4%) patients with disseminated peritoneal adenomucinosis, 5 (14.3%) with peritoneal mucinous carcinomatosis with intermediate group, and 5 (14.3%) with peritoneal mucinous carcinomatosis.
  • The clinical stages at diagnosis were IA in 2 patients, IIIB in 4, IIIC in 23, IV in 1, and unknown in 5.
  • [MeSH-major] Ovarian Neoplasms / complications. Ovarian Neoplasms / pathology. Pseudomyxoma Peritonei / complications. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248391.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Mieda R, Aso C, Nishikawa K, Saito S, Goto F: [Transient hyperglycemia following intra-peritoneal irrigation with 5% glucose in a patient with pseudomyxoma peritonei]. Masui; 2007 Aug;56(8):959-61
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transient hyperglycemia following intra-peritoneal irrigation with 5% glucose in a patient with pseudomyxoma peritonei].
  • Pseudomyxoma peritonei is a condition characterized by the production of a large amount of mucopolysaccharide by a neoplastic epithelium.
  • Although surgical removal of the mucinous ascites may be attempted, complete removal of the material is difficult.
  • Thus, intra-peritoneal lavage with the liquid containing glucose or dextrose has been advocated to prevent reaccumulation of the mucus and complications such as bowel obstruction requiring repeated surgery.
  • We report a case showing transient hyperglycemia following intra-peritoneal irrigation with 5% glucose in a patient with psudomyxoma peritonei.
  • A mucinous tumor was found with a great deal of mucinous ascites.
  • To remove the mucus and prevent subsequent re-accumulation, intra-peritoneal irrigation with 5% glucose in water was performed.
  • Therefore, we think that this acute hyperglycemic condition, presumable due to intra-peritoneal irrigation, was transient.
  • It is important to be aware of this dangerous complication associated with intra-peritoneal glucose instillation.
  • [MeSH-major] Glucose / adverse effects. Hyperglycemia / etiology. Peritoneal Lavage / adverse effects. Postoperative Complications / etiology. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715692.001).
  • [ISSN] 0021-4892
  • [Journal-full-title] Masui. The Japanese journal of anesthesiology
  • [ISO-abbreviation] Masui
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Blood Glucose; IY9XDZ35W2 / Glucose
  •  go-up   go-down


65. Vána J, Adamicová K, Johanes R, Zacharova O, Ammerová E, Solek R: [Appendiceal mucocele causing pseudomyxoma peritonei]. Zentralbl Chir; 2005 Apr;130(2):177-80
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Appendiceal mucocele causing pseudomyxoma peritonei].
  • [Transliterated title] Appendixmukozele als Ursache von Pseudomyxoma peritonei (Gallertbauch).
  • The authors present the case of a very rare pseudomyxoma peritonei as a late complication of appendectomy.
  • The definite diagnosis was established 11 years after appendectomy for appendiceal mucocele.
  • [MeSH-major] Appendectomy / adverse effects. Appendix. Cecal Diseases / complications. Mucocele / complications. Peritoneal Neoplasms / etiology. Pseudomyxoma Peritonei / etiology
  • [MeSH-minor] Adult. Humans. Male. Peritoneum / pathology. Radiography, Abdominal. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849666.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


66. Nonaka D, Kusamura S, Baratti D, Casali P, Younan R, Deraco M: CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Histopathology; 2006 Oct;49(4):381-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases.
  • CDX-2 status in pseudomyxoma peritonei (PMP) has been barely reported.
  • PMP consisted of 32 cases of disseminated peritoneal adenomucinosis and 10 cases of peritoneal mucinous carcinomatosis.
  • The appendix evaluated in 25 cases showed two mucinous adenocarcinomas and 21 low-grade appendiceal mucinous neoplasms.
  • [MeSH-major] Appendiceal Neoplasms / metabolism. Biomarkers, Tumor / analysis. Homeodomain Proteins / metabolism. Peritoneal Neoplasms / metabolism. Pseudomyxoma Peritonei / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Adult. Aged. Carcinoid Tumor / pathology. Disease-Free Survival. Female. Humans. Immunohistochemistry. Keratin-20. Keratin-7. Keratins / metabolism. Male. Middle Aged. Mucin 5AC. Mucin-2. Mucins / metabolism. Neoplasms, Multiple Primary / metabolism. Neoplasms, Multiple Primary / pathology. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978201.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucins; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein; 68238-35-7 / Keratins
  •  go-up   go-down


67. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA: Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome. Ann Surg Oncol; 2007 Feb;14(2):493-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome.
  • BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment strategy for pseudomyxoma peritonei (PMP) with curative intent.
  • The aim of this study was to determine the patterns of failure in patients who underwent such a procedure and to evaluate management and outcome of progressive disease.
  • Progressive disease was mainly located sub hepatic (38%) or in multiple regions (36%).
  • The choice of treatment depended on pathology, extent of disease and PFS.
  • All patients treated for progression by systemic chemotherapy only (n=6) had died of disease after a median follow up of 14.8 (9.8-33.6) months.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Peritoneal Neoplasms / therapy. Peritoneum / surgery. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease Progression. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Failure

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103067.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


68. Sugarbaker PH: Cytoreductive surgery and perioperative intraperitoneal chemotherapy: a new standard of care for appendiceal mucinous tumors with peritoneal dissemination. Clin Colon Rectal Surg; 2005 Aug;18(3):204-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and perioperative intraperitoneal chemotherapy: a new standard of care for appendiceal mucinous tumors with peritoneal dissemination.
  • In the past, mucinous appendiceal tumors and the pseudomyxoma peritonei syndrome were treated with serial debulking procedures.
  • A new standard of care that involves the complete removal of all visible disease using peritonectomy procedures combined with intraperitoneal chemotherapy washing has developed.
  • This new approach is jeopardized when extensive prior surgical procedures have violated the peritoneum as a first line of defense of the host against carcinomatosis.
  • These studies suggest a new standard of care for appendiceal mucinous tumors with peritoneal dissemination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1988 Apr;15(2):129-37 [3285476.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1168-73 [15449269.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):790-6 [10622509.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):164-71 [11266521.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1089-103 [12883241.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):72-80 [15827781.001]
  • [Cites] Cancer. 1973 Dec;32(6):1525-41 [4757938.001]
  • [Cites] Dis Colon Rectum. 1995 Oct;38(10):1110-4 [7555430.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Adv Surg. 1996;30:233-80 [8960339.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Br J Surg. 2000 Oct;87(10):1414-8 [11044169.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):85-91 [11443613.001]
  • [Cites] Gut. 1963 Jun;4:158-68 [13954206.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):109-11 [8129480.001]
  • (PMID = 20011303.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780099
  • [Keywords] NOTNLM ; Cytoreductive surgery / adenomucinosis / intraperitoneal chemotherapy / mucinous carcinomatosis / peritonectomy procedures
  •  go-up   go-down


69. Flatmark K, Davidson B, Kristian A, Stavnes HT, Førsund M, Reed W: Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models. Hum Pathol; 2010 Aug;41(8):1109-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models.
  • Peritoneal surface malignancies are characterized by the propensity for tumor growth on peritoneal surfaces without development of extraperitoneal metastases, but the molecular basis for this phenomenon is incompletely understood.
  • Five human tumors and corresponding orthotopic animal models of human pseudomyxoma peritonei and peritoneal mucinous carcinomatosis from colorectal carcinoma were extensively characterized by immunohistochemical analysis of molecular markers of tissue differentiation (carcinoembryonal antigen, CK20, CK7, and vimentin), proliferation and metastasis (Ki-67, vascular endothelial growth factor, and S100A4), mucins (MUC1, MUC2, MUC4, MUC5AC), and adhesion molecules (E-cadherin, N-cadherin, P-cadherin, claudin 1, claudin 3, and claudin 4).
  • Macro- and microscopic growth patterns of implanted human tissues were preserved through passages in the animals, as were with few exception immunohistochemical staining profiles, supporting the relevance of the models as tools for studying the human disease.
  • These mucinous tumors expressed high levels of MUC2 and MUC4, whereas MUC1 was not expressed and MUC5AC expression was variable.
  • The results indicate that mucinous peritoneal surface malignancies of intestinal origin are characterized by the presence of specific molecular markers and represent a step toward understanding the complexity of this intriguing phenotypic entity.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Mucins / metabolism. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology
  • [MeSH-minor] Aged. Animals. Disease Models, Animal. Female. Humans. Immunohistochemistry. Male. Mice. Middle Aged. Mucin-2 / metabolism. Mucin-4 / metabolism. Neoplasm Transplantation. Peritoneum / metabolism. Phenotype. Pilot Projects


70. Alves S, Mohamed F, Yadegarfar G, Youssef H, Moran BJ: Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Eur J Surg Oncol; 2010 Dec;36(12):1156-61
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.
  • BACKGROUND: Pseudomyxoma peritonei (PMP) is characterized by mucinous ascites, predominantly arising form a perforated tumour of the appendix.
  • One patient died from progressive disease three months from surgery and two patients withdrew from the study within 6 months of surgery.
  • Patients undergoing both complete cytoreduction and major tumour debulking reported a clinically significant improvement in emotional well-being, appetite and global HRQL at 1 year following surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hyperthermia, Induced. Infusions, Parenteral. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20864306.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


71. Shirasawa Y, Orita H, Ishida K, Morimoto Y, Matsumoto M, Sakabe T: Critical alkalosis following intraperitoneal irrigation with sodium bicarbonate in a patient with pseudomyxoma peritonei. J Anesth; 2008;22(3):278-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical alkalosis following intraperitoneal irrigation with sodium bicarbonate in a patient with pseudomyxoma peritonei.
  • Pseudomyxoma peritonei (PMP) is a rare disease, presenting with large amounts of mucinous ascites, and treatment with intraperitoneal irrigation with mucolytic agents has been tried.
  • The patient was a 78-year-old woman who had mucinous ascites, and an appendiceal and an ovarian tumor.
  • [MeSH-major] Alkalosis / chemically induced. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / surgery. Sodium Bicarbonate / adverse effects
  • [MeSH-minor] Aged. Appendiceal Neoplasms / surgery. Blood Gas Analysis. Electrolytes / blood. Female. Humans. Ovarian Neoplasms / surgery. Peritoneal Lavage / methods

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. SODIUM BICARBONATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685934.001).
  • [ISSN] 0913-8668
  • [Journal-full-title] Journal of anesthesia
  • [ISO-abbreviation] J Anesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Electrolytes; 8MDF5V39QO / Sodium Bicarbonate
  •  go-up   go-down


72. Khan AB, Al Suhaibani Y, Al Mohaimed K, Morris DL: Application of advanced multimodality care to pseudomyxoma peritonei patient: report of first patient treated at a tertiary center. Indian J Surg Oncol; 2010 Sep;1(3):270-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of advanced multimodality care to pseudomyxoma peritonei patient: report of first patient treated at a tertiary center.
  • Pseudomyxoma peritonei following dissemination of appendicealmucinous neoplasms is slowly progressive but inevitably a lethal condition.
  • We present a case of pseudomyxoma peritonei treated by Cytoreductive surgery(CRS)and heated intraperitoneal chemotherapy(HIPEC) with Mitomycin C (12.5mg/m2 ) at 41.50 C.
  • Histopathology revealed Pseudomyxoma peritonei (hybrid type).
  • The patient recuperated well and was discharged and now is living a productive life.
  • Peritonectomy with perioperative intraperitoneal chemotherapy is the current standard of treatment for appendiceal tumors with peritoneal dissemination which offers a hope of disease free long survival in such patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22693376.001).
  • [ISSN] 0976-6952
  • [Journal-full-title] Indian journal of surgical oncology
  • [ISO-abbreviation] Indian J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3244241
  • [Keywords] NOTNLM ; Appendix / Hyper thermic chemotherapy / Intraperitoneal / Mucinous tumors / Peritoneal dissemination / Peritonectomy / Pseudomyxoma peritonei
  •  go-up   go-down


73. Semino-Mora C, Liu H, McAvoy T, Nieroda C, Studeman K, Sardi A, Dubois A: Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol; 2008 May;15(5):1414-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
  • BACKGROUND AND AIMS: Pseudomyxoma peritonei (PMP) is characterized by peritoneal tumors arising from a perforated appendiceal adenoma or adenocarcinoma, but associated entry of enteric bacteria in the peritoneum has not been considered as a cofactor.
  • METHODS: In situ hybridization was performed on resection specimens from five control subjects with noninflamed, nonperforated, non-neoplastic appendix and 16 patients with PMP [six with disseminated peritoneal adenomucinosis (DPAM) and 10 with peritoneal mucinous carcinomatosis (PMCA)].
  • Based on these observations, we propose that the bacteria observed in PMP may play a role in the mucinous ascites and perhaps promote carcinogenesis.

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infect Immun. 1993 May;61(5):1799-809 [8478069.001]
  • [Cites] Lancet. 1992 Nov 14;340(8829):1194-5 [1359263.001]
  • [Cites] J Histochem Cytochem. 1995 Feb;43(2):115-23 [7529784.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] Clin Infect Dis. 1996 Jul;23(1):101-6 [8816137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):967-72 [9023366.001]
  • [Cites] Mutat Res. 1997 Jun 13;391(1-2):79-86 [9219551.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1128-33 [9781653.001]
  • [Cites] Toxicon. 1999 May;37(5):815-23 [10219991.001]
  • [Cites] J Immunol. 1999 May 15;162(10):6233-7 [10229869.001]
  • [Cites] Ann Chir. 2005 Feb;130(2):63-9 [15737316.001]
  • [Cites] Lab Invest. 2005 May;85(5):702-15 [15765119.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1372-9 [15909071.001]
  • [Cites] Helicobacter. 2006 Feb;11(1):2-9 [16423084.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):551-9 [16699309.001]
  • [Cites] Cancer Lett. 2006 Nov 28;244(1):86-90 [16427185.001]
  • [Cites] Inflamm Bowel Dis. 2006 Nov;12(11):1068-83 [17075348.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e110 [17121461.001]
  • [Cites] Gastroenterology. 2007 Feb;132(2):551-61 [17258726.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):1009-23 [17383424.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):943-53; discussion 953-5 [17481516.001]
  • [Cites] Biochim Biophys Acta. 1998 Apr 28;1406(3):251-9 [9630659.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):458-63 [11260116.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):164-71 [11266521.001]
  • [Cites] J Radiol. 2001 Apr;82(4):463-8 [11353901.001]
  • [Cites] Surg Today. 2001;31(7):646-50 [11495161.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2253-7 [12057927.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):551-64 [12163380.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):958-72 [12218214.001]
  • [Cites] Mol Pharmacol. 2002 Nov;62(5):1112-8 [12391274.001]
  • [Cites] J Obstet Gynaecol. 2002 Mar;22(2):223 [12521714.001]
  • [Cites] J Infect Dis. 2003 Apr 15;187(8):1165-77 [12695995.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8 [12911716.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):178-86 [14761921.001]
  • [Cites] Ann Intern Med. 2004 Apr 20;140(8):W33 [15096365.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17 [15194558.001]
  • [Cites] Acta Chir Scand. 1973;139(4):392-400 [4718184.001]
  • [Cites] J Histochem Cytochem. 1987 Sep;35(9):983-96 [3302022.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1636-40 [2208015.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):112-9 [8129481.001]
  • (PMID = 18299935.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA082312-08; United States / NCI NIH HHS / CA / R01 CA082312; United States / NCI NIH HHS / CA / CA82312; United States / NCI NIH HHS / CA / R01 CA082312-08
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Probes; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucins; 0 / RNA Probes
  • [Other-IDs] NLM/ NIHMS72052; NLM/ PMC2570966
  •  go-up   go-down


74. Ceelen W, Van Nieuwenhove Y, Pattyn P: Surgery and intracavitary chemotherapy for peritoneal carcinomatosis from colorectal origin. Acta Gastroenterol Belg; 2008 Oct-Dec;71(4):373-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and intracavitary chemotherapy for peritoneal carcinomatosis from colorectal origin.
  • A subset of patients with colorectal cancer (CRC) develops synchronous or metachronous isolated peritoneal disease.
  • The development of peritoneal carcinomatosis (PC) can be conceptualized as a series of well defined steps including cell shedding, adhesion to mesothelial cells and underlying matrix, and invasion of submesothelial tissue.
  • Surgical cytoreduction combined with hyperthermic intraperitoneal chemoperfusion (HIPEC) has evolved as the standard of care in patients with mucinous appendiceal tumors including the pseudomyxoma peritonei syndrome.
  • Recently, this approach was extended to patients with peritoneal carcinomatosis (PC) from non appendiceal CRC.
  • In this review, we discuss the biological rationale, clinical methods, and oncological outcomes associated with cytoreduction and intracavitary chemotherapy in CRC patients suffering from peritoneal disease spread.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Carcinoma / surgery. Colorectal Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317277.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 52
  •  go-up   go-down


75. Mall AS, Chirwa N, Govender D, Lotz Z, Tyler M, Rodrigues J, Kahn D, Goldberg P: MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study. Pathol Int; 2007 Aug;57(8):537-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study.
  • A 58-year-old man with a 1 year history of progressive abdominal distension underwent a laparotomy for pseudomyxoma peritonei.
  • Approximately 6 L of crude mucus in the sol (highly viscous) and gel (semisolid) phases was obtained from the patient's peritoneal cavity.
  • Histopathological examination confirmed a mucinous appendicular adenocarcinoma.
  • [MeSH-major] Mucins / metabolism. Mucus / metabolism. Peritoneal Neoplasms / metabolism. Pseudomyxoma Peritonei / metabolism
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secretion. Adenocarcinoma / surgery. Aged. Appendiceal Neoplasms / pathology. Appendiceal Neoplasms / secretion. Appendiceal Neoplasms / surgery. Biomarkers, Tumor / metabolism. Humans. Male. Mucin 5AC. Mucin-2. Mucin-5B. Palliative Care. Treatment Outcome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17610480.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC5B protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucin-5B; 0 / Mucins
  •  go-up   go-down


76. Maheshwari V, Tsung A, Lin Y, Zeh HJ 3rd, Finkelstein SD, Bartlett DL: Analysis of loss of heterozygosity for tumor-suppressor genes can accurately classify and predict the clinical behavior of mucinous tumors arising from the appendix. Ann Surg Oncol; 2006 Dec;13(12):1610-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of loss of heterozygosity for tumor-suppressor genes can accurately classify and predict the clinical behavior of mucinous tumors arising from the appendix.
  • BACKGROUND: Pseudomyxoma peritonei is a rare heterogenous clinical syndrome with a variable clinical course.
  • On the basis of the hypothesis that cumulative mutational damage can predict biological aggressiveness, we evaluated the utility of integrated histopathology and molecular analysis for patients with pseudomyxoma peritonei syndrome.
  • METHODS: Tissue specimens from 23 mucinous appendiceal tumors were analyzed.
  • In addition, there was also an association between the FMR and pathological classification as well as between the FMR and survival (P < .05).
  • An FMR less than .25 indicated low-grade disease, an FMR of .25 to .50 indicated intermediate grade, and an FMR greater than .5 indicated a high-grade tumor.
  • CONCLUSIONS: Mutational profiling of accumulated allelic loss and point mutational damage correlated strongly with histopathologic definitions of pseudomyxoma peritonei disease and helped to predict the prognosis of these patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Appendiceal Neoplasms / genetics. Genes, Tumor Suppressor. Loss of Heterozygosity / genetics. Pseudomyxoma Peritonei / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009159.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


77. Ardavanis A, Sykoutri D, Kountourakis P, Doufexis D, Korkolis D, Tzerbini H, Skarlatos I, Mosa E, Rigatos G: Paraneoplastic cerebellar degeneration in a patient with pseudomyxoma peritonei and breast cancer: case report and literature review. In Vivo; 2009 Sep-Oct;23(5):835-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic cerebellar degeneration in a patient with pseudomyxoma peritonei and breast cancer: case report and literature review.
  • The case of a 31-year-old woman with progressive cerebellar degeneration preceding by several months the diagnosis and treatment of breast cancer initially and pseudomyxoma peritonei (PMP) with evidence of causative association with the latter is presented.
  • Despite various chemotherapeutic and surgical manipulations, the patient did not substantially improve and succumbed 20 months following initial diagnosis of the neurological disorder.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Paraneoplastic Cerebellar Degeneration / pathology. Pseudomyxoma Peritonei / pathology


78. Chua TC, Al-Zahrani A, Saxena A, Liauw W, Zhao J, Morris DL: Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation. J Am Coll Surg; 2010 Oct;211(4):526-35
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation.
  • BACKGROUND: Cytoreductive surgery and perioperative intraperitoneal chemotherapy (PIC) is recognized as an effective treatment modality for patients with pseudomyxoma peritonei.
  • STUDY DESIGN: Patients with pseudomyxoma peritonei undergoing secondary cytoreduction combined with PIC were identified from a prospective database.
  • Median overall survival from initial diagnosis was 17 years and 10-year survival rate was 75%.
  • Forty-five patients remained disease free (63%).
  • Requiring an urgent treatment (waiting time < 60 days) after disease progression (p = 0.045) and having moderate or severe symptoms (p = 0.033) were associated with a shorter time to progression.
  • Improved survival was associated with patients who had low-grade tumors (p = 0.029), and those who required less urgent treatment (wait > 30 days) after disease progression (waiting up to 15 days, p = 0.010; waiting up to 30 days, p = 0.005).
  • Malignant dedifferentiation appeared to affect survival from initial diagnosis (p = 0.062) and after secondary cytoreduction (p = 0.006).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Adult. Cell Differentiation. Cell Transformation, Neoplastic. Disease Progression. Female. Fluorouracil / administration & dosage. Humans. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Prognosis. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American College of Surgeons. All rights reserved.
  • [CommentIn] J Am Coll Surg. 2011 May;212(5):906; author reply 907 [21530846.001]
  • (PMID = 20729102.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


79. Jess P, Iversen LH, Nielsen MB, Hansen F, Laurberg S, Rasmussen PC: Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study. Dis Colon Rectum; 2008 Jun;51(6):868-74
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study.
  • PURPOSE: The modern treatment of pseudomyxoma peritonei is cytoreductive surgery plus intraperitoneal chemotherapy resulting in a survival of up to 70 percent after 20 years.
  • METHODS: Twenty-three prospective patients underwent cytoreductive surgery and early postoperative intraperitoneal chemotherapy for pseudomyxoma peritonei.
  • The impact on quality of life of the disease and of its treatment was very modest despite the high morbidity after the treatment.
  • CONCLUSIONS: Cytoreductive surgery plus early postoperative intraperitoneal chemotherapy is an extensive treatment with a high morbidity but with relatively little impact on quality of life in patients with pseudomyxoma peritonei.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery. Quality of Life

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297361.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


80. Saxena A, Yan TD, Chua TC, Morris DL: Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol; 2010 May;17(5):1291-301
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei.
  • BACKGROUND: Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) has demonstrated improved survival in selected patients with pseudomyxoma peritonei (PMP).
  • Eight factors were associated with grade IV/V morbidity on univariable analysis: peritoneal cancer index >or=21 (P = .034), ASA score >or=3 (P = .003), operation duration >or=10 h (P < .001), left upper quadrant peritonectomy procedure (P = .037), colonic resection (P = .012), ostomy (P = .005), ileostomy (P = .012), and transfusion >or=6 units (p = 0.011).
  • Patients with bulky disease who undergo a long operation are at a particularly high risk of a severe adverse event.
  • [MeSH-major] Adenocarcinoma, Mucinous / mortality. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / mortality. Postoperative Complications / mortality. Pseudomyxoma Peritonei / mortality

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2011 Jan;18(1):282-3; author reply 284-5 [20645012.001]
  • (PMID = 20039212.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Naidu LS, Jobling JC: Chronic colonic perforation in pseudomyxoma peritonei. Br J Radiol; 2007 May;80(953):e94-7
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic colonic perforation in pseudomyxoma peritonei.
  • Pseudomyxoma peritonei (PP) produces abundant mucoid material from the rupture of low grade ovarian or appendiceal mucinous tumours.
  • It has diverse presentations, mainly as a result of narrowing of the gastrointestinal tract and entrapment of other viscera by gelatinous mucoid material.
  • We report a patient with pseudomyxoma perotonei who had perforation at the recto-sigmoid junction into a large mucinous cyst adjacent to the sigmoid colon.
  • [MeSH-major] Intestinal Perforation / radiography. Peritoneal Neoplasms / radiography. Pseudomyxoma Peritonei / radiography. Rectal Diseases / radiography. Sigmoid Diseases / radiography
  • [MeSH-minor] Aged. Chronic Disease. Cysts / radiography. Enema / methods. Humans. Male. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638839.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Goldstein PJ, Cabanas J, da Silva RG, Sugarbaker PH: Pseudomyxoma peritonei arising from colonic polyps. Eur J Surg Oncol; 2006 Sep;32(7):764-6
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei arising from colonic polyps.
  • AIMS: Pseudomyxoma peritonei may have as its primary site a mucinous gastrointestinal adenoma or carcinoma that gains access to the peritoneal cavity.
  • This manuscript describes this disease arising from a benign or malignant colonic polyp.
  • METHODS: From a database of over 1000 pseudomyxoma peritonei patients and colorectal carcinomatosis patients, three cases were identified in which the primary tumor site was a colonic polyp.
  • RESULTS: In a review of the clinical management of these patients, all three had an event whereby neoplastic cells from the surface of the colonic polyp could have gained access to the free peritoneal cavity.
  • The patients developed the characteristic pseudomyxoma peritonei syndrome.
  • CONCLUSIONS: Colonic polyps can serve as a source of dysplastic cells whereby pseudomyxoma peritonei can result.
  • Caution to prevent seeding to the free peritoneal cavity during surgery for colonic polyps should be observed.
  • If pseudomyxoma peritonei develops, cytoreductive surgery and perioperative intraperitoneal chemotherapy should be considered for treatment.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Pseudomyxoma Peritonei / etiology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenoma, Villous / pathology. Adenoma, Villous / surgery. Adult. Aged. Female. Humans

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765563.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Hosaka A, Masaki Y, Yamasaki K, Aoki F, Sugizaki K: Pseudomyxoma peritonei presenting with femoral hernias and peritonitis. J Gastrointest Surg; 2007 Nov;11(11):1576-8
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei presenting with femoral hernias and peritonitis.
  • Pseudomyxoma peritonei is a rare disease characterized by intraperitoneal accumulation of mucinous ascites produced by neoplastic cells, which mostly originate from an appendiceal adenoma.
  • The clinical presentation of the disease varies, and preoperative diagnosis is often difficult.
  • This report describes a 76-year-old female patient with pseudomyxoma peritonei who presented with lower abdominal pain and bilateral femoral masses.
  • Computed tomography revealed bilateral femoral hernias and fluid collection in the peritoneal cavity.
  • Laparotomy was performed, during which we found extensive diffuse gelatinous material mixed with purulent ascites, and the diagnosis of pseudomyxoma peritonei was confirmed.
  • The disease is rarely associated with femoral hernias or peritonitis.
  • [MeSH-major] Hernia, Inguinal / etiology. Peritonitis / etiology. Pseudomyxoma Peritonei / diagnosis
  • [MeSH-minor] Aged. Female. Humans. Peritoneal Neoplasms / radiography. Peritoneal Neoplasms / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508254.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Homeag M, Enachescu V, Pavel LE, Zaharia B, Manescu N: Pseudomyxoma peritonei. Curr Health Sci J; 2009 Jul;35(3):193-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei.
  • The authors report a case of a 60 years old Romanian male with peritoneal pseudomyxoma that was discovered to have a primary location in the greater omentum.
  • Pseudomyxoma peritonei arising into the greater omentum is very rare.
  • It is an original case report and the new data represents a well-balanced summary of a timely subject, with reference to the literature.
  • This it is a significantly advance in our understanding of a particular disease etiology.
  • Until now, only a few primary greater omentum pseudomyxoma peritonei have been described.
  • Clinical and pathologic findings of this case are presented and the topic of primary location in the great omentum of pseudomyxoma peritonei was reviewed.
  • Notwithstanding, diagnosis of pseudomyxoma was preoperatively considered less probable due to the rarity of the affection and the advanced age.
  • Mucinous ascites was present with invasive mucinous implants in the peritoneum and in the greater omentum.
  • Operation consisted in the total removal of the mass followed by evacuation of the mucinous ascites.
  • Histological examination confirmed the clinical diagnosis of pseudomyxoma peritonei.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24778820.001).
  • [ISSN] 2067-0656
  • [Journal-full-title] Current health sciences journal
  • [ISO-abbreviation] Curr Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Other-IDs] NLM/ PMC3945247
  • [Keywords] NOTNLM ; fibrous / peritoneum / pseudomyxoma / ultrasound examination
  •  go-up   go-down


85. vanSonnenberg E, Goodacre BW, Wittich GR, Ali S, Silverman SG, Shankar S, Tuncali K: Interventional radiology strategies in the treatment of pseudomyxoma peritonei. Cardiovasc Intervent Radiol; 2005 Jul-Aug;28(4):490-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventional radiology strategies in the treatment of pseudomyxoma peritonei.
  • PURPOSE: To describe percutaneous maneuvers to treat the unusual entity symptomatic pseudomyxoma peritonei (PMP).
  • [MeSH-major] Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / therapy. Radiography, Interventional / methods

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034657.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B: Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence. Colorectal Dis; 2005 Jul;7(4):382-6
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence.
  • OBJECTIVE: To assess the potential value of pre-operative CEA, CA 125 and CA 19-9 in identifying Pseudomyxoma peritonei (PMP) patients at risk of recurrence following complete cytoreductive surgery and intraperitoneal chemotherapy.
  • The most common abnormality was elevated CEA level in 14/32[44%].
  • The 2-year disease free intervals were 100% in 9 patients with normal preop markers compared with 66% for the group with at least one abnormal marker.
  • CONCLUSION: PMP patients with elevated CEA, or more than one abnormal serum tumour maker, are at risk of developing recurrent disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Neoplasm Recurrence, Local / blood. Peritoneal Neoplasms / blood. Pseudomyxoma Peritonei / blood

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15932563.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 50SG953SK6 / Mitomycin
  •  go-up   go-down


87. Chua TC, Akther J, Yao P, Morris DL: In vivo model of pseudomyxoma peritonei for novel candidate drug discovery. Anticancer Res; 2009 Oct;29(10):4051-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo model of pseudomyxoma peritonei for novel candidate drug discovery.
  • Pseudomyxoma peritonei (PMP) is a clinical condition characterized by diffuse intraabdominal spread of mucinous tumor implants that form on peritoneal surfaces.
  • To develop a model for drug discovery, human pseudomyxoma peritonei tumor implants consisting of a mixture of mucin and epithelial cells were injected into the peritoneal cavity of CBH/rnu/rnu rats.
  • [MeSH-major] Drug Discovery / methods. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology. Xenograft Model Antitumor Assays / methods

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846950.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


88. Meshikhes AW, Al-Abkari HA, Al-Momen SA, Saad FE: Pseudomyxoma peritonei. Saudi Med J; 2006 Mar;27(3):389-91
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei.
  • Pseudomyxoma peritonei is very rare, and its exact pathogenesis is unknown.
  • It is characterized by intra-abdominal extracellular gelatinous fluid collections.
  • We report a case of pseudomyxoma peritonei in a 38-year-old Saudi male who presented with right iliac fossa mass and weight loss.
  • He was treated initially as an appendicular mass and computed tomography was helpful in making the diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Intestinal Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Pseudomyxoma Peritonei / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532086.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


89. McKenney JK, Soslow RA, Longacre TA: Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol; 2008 May;32(5):645-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
  • Mucinous epithelial neoplasms arising in association with mature teratomas are a heterogeneous group of tumors, but with the exception of a single recent study, their full histologic spectrum, detailed immunophenotype, and association with classic pseudomyxoma peritonei (PMP) have not been fully studied.
  • The morphologic, immunohistochemical, and clinical features of 42 patients with mucinous epithelial tumors arising in association with mature ovarian teratomas were evaluated.
  • Most teratoma-associated mucinous tumors were unilateral, although 1 patient harbored bilateral mucinous tumors in association with bilateral teratomas.
  • Using the 2003 World Health Organization criteria for ovarian intestinal type mucinous neoplasms, 17 (40%) were classified as mucinous cystadenoma, 16 (38%) as intestinal-type mucinous epithelial neoplasm of low malignant potential (IM-LMP), 4 (10%) as intraepithelial carcinoma (IEC), and 5 (12%) as invasive mucinous carcinoma.
  • Mucinous cystadenomas had a varied epithelial lining consisting of lower gastroenteric, gastric foveolar, or müllerian appearance.
  • For mucinous cystadenomas, a cytokeratin (CK) 7+/CK20- phenotype (5/13; 38%) was equally as common as a CK7-/CK20+ phenotype (5/13; 38%), with the remaining cases coexpressing both keratins (CK7+/CK20+: 3/13; 23%).
  • A CK7+/CK20-phenotype was rare in these later 3 morphologic groups (6%).
  • Of the 42 total cases, 55% had pseudomyxoma ovarii and 24% had classic PMP (1 cystadenoma, 6 IM-LMP, and 3 invasive carcinomas), whereas 5% had more localized accumulations of peritoneal mucin (both IM-LMP).
  • Pathologic evaluation of the peritoneum in these 12 cases revealed 6 with acellular mucin alone, 3 with low-grade mucinous epithelium (all 3 with ovarian IM-LMP), and 3 with high-grade mucinous carcinomatosis (all 3 with ovarian mucinous adenocarcinoma).
  • The only adverse outcomes occurred in the 3 patients with ovarian carcinoma and associated peritoneal carcinomatosis.
  • We report that a significant proportion of mucinous tumors associated with mature ovarian teratomas present with clinical PMP, which in most cases is associated with IM-LMP.
  • PMP in this setting may harbor microscopic intra-abdominal low-grade mucinous epithelium that is histologically and immunophenotypically similar to that typically seen in appendiceal-related PMP.
  • Pseudomyxoma ovarii is common in this setting, particularly in tumors with IM-LMP histology, but pseudomyxoma ovarii is not predictive of PMP.
  • Ovarian teratoma-associated benign and IM-LMP mucinous neoplasms with microscopic peritoneal low-grade mucinous epithelium do not seem to be at significant risk for intra-abdominal recurrence, but numbers are few and follow-up is limited.
  • In contrast, teratomas with an invasive carcinomatous component and microscopic peritoneal carcinomatosis follow an aggressive clinical course.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344868.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


90. Smeenk RM, Verwaal VJ, Zoetmulder FA: [Pseudomyxoma peritonei; a rare tumour that can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy]. Ned Tijdschr Geneeskd; 2007 Feb 17;151(7):418-23
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudomyxoma peritonei; a rare tumour that can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
  • [Transliterated title] Pseudomyxoma peritonei; een zeldzame tumor, te behandelen met cytoreductieve chirurgie en hypertherme intraperitoneale chemotherapie.
  • All three were diagnosed with pseudomyxoma peritonei.
  • After a mean follow-up of 64 months (range: 19-89) after initial treatment, the second patient had died of disease progression but the other two were alive and free of disease.
  • Pseudomyxoma peritonei is a rare disease, characterised by progressive intraperitoneal accumulation of mucinous ascites, produced by a mucinous tumour mass on the peritoneal surfaces.
  • The primary tumour is usually a mucinous adenoma of the appendix.
  • Recognising pseudomyxoma peritonei in an early stage, when complete cytoreduction is still achievable, may result in a considerable improvement in survival.
  • [MeSH-major] Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343142.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


91. Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA: Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol; 2008 Feb;34(2):196-201
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal neoplasms and pseudomyxoma peritonei: a population based study.
  • BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare disease with an estimated incidence of 1 per million per year, and is thought to originate usually from an appendiceal mucinous epithelial neoplasm.
  • A mucinous epithelial neoplasm was identified in 0.3% (73% benign, 27% malignant) of appendiceal specimens and 20% of these patients developed PMP.
  • For mucocele and non-mucinous neoplasm the association with PMP was only 2% and 3%, respectively.
  • One third of these lesions are mucinous epithelial neoplasms and especially these tumours may progress into PMP.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Appendiceal Neoplasms / epidemiology. Neoplasms, Multiple Primary / epidemiology. Peritoneal Neoplasms / epidemiology. Pseudomyxoma Peritonei / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524597.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG: Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg; 2005 Feb;241(2):300-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy.
  • SUMMARY BACKGROUND DATA: Pseudomyxoma peritonei (PMP) is a clinical syndrome with a poorly defined natural history.
  • Relative contributions of tumor biology, patient selection, and the extent of treatment on ultimate outcome are not well characterized.
  • METHODS: Patients treated at the Memorial Sloan-Kettering Cancer Center between 1980 and 2002 with a diagnosis of PMP were identified.
  • Although complete cytoreduction was achieved in 55% (53/97), disease recurred in 91% (48/53) of patients.
  • The median disease-free interval after complete cytoreduction was 24 months.
  • At the time of death or completion of follow-up, only 12% (12/97) of the patients were disease free.
  • Treatment may be beneficial, particularly in controlling symptoms, but absolute cure, defined as a prolonged disease-free state, is uncommon.
  • [MeSH-major] Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Patient Selection

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2000 Oct;87(10):1414-8 [11044169.001]
  • [Cites] Surg Clin North Am. 2000 Apr;80(2):471-86, viii [10836002.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):85-91 [11443613.001]
  • [Cites] Am Heart J. 2001 Nov;142(5):745-7 [11685157.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):696-703 [12167585.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):72-9 [12513964.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):396-401 [1319813.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):109-11 [8129480.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):112-9 [8129481.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):591-603 [8179074.001]
  • [Cites] Obstet Gynecol. 1994 Jul;84(1):17-21 [8008316.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):671-9 [8636786.001]
  • [Cites] Adv Surg. 1996;30:233-80 [8960339.001]
  • [Cites] Arch Surg. 1997 Apr;132(4):338-46 [9108752.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1332-9 [9782010.001]
  • [Cites] World J Surg. 1999 Jan;23(1):23-9 [9841759.001]
  • [Cites] Am J Surg. 1999 Feb;177(2):150-4 [10204560.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):239-43 [11373099.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):797-801 [10622510.001]
  • [CommentIn] Ann Surg. 2005 Nov;242(5):748-50; author reply 750-1 [16244553.001]
  • (PMID = 15650641.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1356916
  •  go-up   go-down


93. Sun WL, Hutarew G, Gradl J, Gratzl M, Denz H, Fiegl M: Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine. Cancer Biol Ther; 2009 Aug;8(15):1459-62
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine.
  • Effective systemic therapy for advanced pseudomyxoma peritonei (PMP) is the focus of investigation.
  • Upon progressive disease, a combination of bevacizumab and capecitabine led to a long term stabilization of disease and obvious improvement of performance status.
  • [MeSH-major] Adenoma, Villous / secondary. Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / complications. Peritoneal Neoplasms / secondary. Pseudomyxoma Peritonei / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Capecitabine. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Hernia, Inguinal / complications. Hernia, Inguinal / surgery. Humans. Ileocecal Valve / surgery. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483475.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


94. Ferreira CR, Carvalho JP, Soares FA, Siqueira SA, Carvalho FM: Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):59-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors.
  • Pseudomyxoma peritonei (PMP) is a clinical condition initially thought to be related to ovarian mucinous tumors; however, immunohistochemistry and molecular biology techniques have convincingly made the link to appendiceal mucinous neoplasms, resulting in changes in histologic and clinical approaches.
  • The objective of this study was to compare the immunohistochemical profile of ovarian tumors associated with PMP and intestinal mucinous ovarian neoplasms without PMP.
  • The study was retrospective and included 28 intestinal ovarian mucinous tumors selected from the files of the Division of Surgical Pathology of the University of Sao Paulo Medical School, from 1996 to 2005.
  • Seven cases were associated with PMP of disseminated peritoneal adenomucinosis-type and all presented borderline histology.
  • Our results confirm that there is a distinct profile of intestinal ovarian tumors associated with pseudomyxoma, particularly with respect to the expression of the gel-forming mucin MUC2.
  • The profile of borderline tumors, even in cases without PMP, was distinct from that of other primary mucinous tumors of the intestinal type, suggesting that borderline histology may represent a secondary tumor or a less aggressive variant of PMP.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Biomarkers, Tumor / metabolism. Intestinal Neoplasms / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511804.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Mucins
  •  go-up   go-down


95. Loungnarath R, Causeret S, Brigand C, Gilly FN, Glehen O: [Pseudomyxoma peritonei: new concept and new therapeutic approach]. Ann Chir; 2005 Feb;130(2):63-9
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudomyxoma peritonei: new concept and new therapeutic approach].
  • [Transliterated title] Pseudomyxome péritonéal ou maladie gélatineuse du péritoine: nouveaux concepts et nouvelle prise en charge thérapeutique.
  • Pseudomyxoma peritonei is a rare disease, usually diagnosed after the discover of "jelly belly" by laparotomy.
  • With the progress of immunohistochemistry, most authors now acknowledge the appendix to be the principal origin of this disease.
  • Pseudomyxoma peritonei need to considered as border line malignant disease because of its inevitable persistence and progression without adapted therapeutic approach: cytoreductive surgery combined with perioperative intraperitoneal chemotherapy (intraperitoneal chemohyperthermia and/or immediate postoperative intraperitoneal chemotherapy) into specialized centres.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Hyperthermia, Induced. Infusions, Parenteral. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737316.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 43
  •  go-up   go-down


96. Yonemura Y, Bando E, Kawamura T, Tsukiyama G, Itou H, Akamoto S, Nemoto M, Yang QM, Shinpo M, Hashimoto K, Sugarbaker PH, Ikeno T: [The results of surgical treatment for pseudomyxoma peritonei]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1822-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The results of surgical treatment for pseudomyxoma peritonei].
  • The surgical results of 37 patients with pseudomyxoma pertonei are reported.
  • However, 13 patients received incomplete cytoreduction, and 9 patients underwent drainage of ascites and peritoneal washing.
  • The Peritoneal Carcinomatosis Index (PCI) was less than 20 in CC-0 patients.
  • CC-0 patients survived significantly better than patients with residual disease.
  • Accordingly, peritoneal washing to remove free cancer cells should be aimed for complete cytoreduction of the solid mucinous nodules.
  • [MeSH-major] Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drainage. Female. Humans. Laparotomy. Male. Middle Aged. Peritoneal Lavage. Surgical Procedures, Operative / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212118.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


97. Hwang JH, So KA, Modi G, Lee JK, Lee NW, Lee KW, Kim I: Borderline-like mucinous tumor arising in mature cystic teratoma of the ovary associated with pseudomyxoma peritonei. Int J Gynecol Pathol; 2009 Jul;28(4):376-80
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline-like mucinous tumor arising in mature cystic teratoma of the ovary associated with pseudomyxoma peritonei.
  • SUMMARY: Pseudomyxoma peritonei (PMP) is now considered to originate from appendiceal mucinous neoplasms in almost all cases.
  • However, a mucinous neoplasm arising in a mature cystic teratoma is rarely responsible for PMP.
  • We herein report 2 cases of PMP associated with borderline mucinous tumors arising in mature cystic teratoma.
  • Both ovarian borderline mucinous tumors were morphologically and immunohistochemically similar to the secondary tumors from appendiceal origin, and PMP was histologically similar to peritoneal adenomucinosis.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483624.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Niwa K, Hirose R, Mizuno T, Hirose Y, Tamaya T: Pseudomyxoma peritonei and mucinous pyometral fluid arising from an ovarian borderline mucinous tumor: case report. Eur J Gynaecol Oncol; 2007;28(2):145-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei and mucinous pyometral fluid arising from an ovarian borderline mucinous tumor: case report.
  • An extremely rare case of a pseudomyxoma peritonei (PMP) and mucinous pyometral fluid, possibly arising from an ovarian borderline mucinous tumor is reported.
  • A 68-year-old Japanese patient received an expolatory laparatomy under a working diagnosis of a PMP, left ovarian cystic tumor and an umbilical hernia.
  • Surgery and platinum-based chemotherapy induced a 15-month disease-free condition.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous. Aged. Combined Modality Therapy. Female. Humans. Ovary / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17479681.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


99. Bibi R, Pranesh N, Saunders MP, Wilson MS, O'dwyer ST, Stern PL, Renehan AG: A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. Br J Cancer; 2006 Nov 6;95(9):1258-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.
  • Pseudomyxoma peritonei (PMP) is a rare neoplasm of mainly appendiceal origin, characterised by excess intra-abdominal mucin production leading to high morbidity and mortality.
  • While histological features are frequently indolent, this tumour disseminates aggressively throughout the abdominal cavity, yet seldom metastasises.
  • This study determined the expression of several markers of colorectal differentiation (carcinoembryonic antigen (CEA), cytokeratins (CK20 and CK7), epithelial membrane antigen), mucin production (MUC-2, interleukin-9 (IL-9), IL-9 receptor (IL-9Ralpha)), and cell adhesion (N- and E-cadherin, vimentin) in PMP tissue (n=26) compared with expressions in normal colonic mucosa (n=19) and colorectal adenocarcinoma (n=26).
  • Similarly, expressions of mucin-related proteins were comparable for adenocarcinoma and PMP, with the exception that IL-9 expression was uncommon in adenocarcinoma (P=0.009).
  • Pseudomyxoma peritonei demonstrated a specific pattern of adhesion-related protein expressions of increased N-cadherin, reduced E-cadherin, and increased vimentin (P=0.004), a phenotype suggesting a possible epithelial-mesenchymal transition state.
  • These early characterisation studies demonstrate similarities between PMP and colorectal adenocarcinoma, but also reveal a specific cadherin phenotype that may characterise the distinct non-metastasising behaviour of PMP, and form the basis for future mechanistic and therapy-targeting research.
  • [MeSH-major] Cadherins / analysis. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Interleukin-9 / analysis. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Mucin-1 / analysis. Mucin-2. Mucins / analysis. Neoplasm Metastasis. Receptors, Interleukin-9 / analysis. Tumor Cells, Cultured. Vimentin / analysis

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2001 Jul;32(7):690-7 [11486167.001]
  • [Cites] Br J Surg. 2000 Oct;87(10):1414-8 [11044169.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):958-72 [12218214.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):1037-42 [12782818.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1089-103 [12883241.001]
  • [Cites] J Surg Oncol. 2004 Apr 1;86(1):10-5 [15048674.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):711-9 [15252840.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):798-806 [3940644.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Am J Surg Pathol. 1993 Jan;17(1):22-34 [8383467.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):981-6 [7682766.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3241-5 [8324734.001]
  • [Cites] Pathol Res Pract. 1993 Sep;189(8):862-6 [8302707.001]
  • [Cites] Hum Pathol. 1995 May;26(5):509-24 [7750935.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):999-1001 [7657131.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] J Cell Biol. 1996 Dec;135(6 Pt 1):1643-54 [8978829.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1997 Feb;9(2):183-6 [9058631.001]
  • [Cites] Cell Adhes Commun. 1997 Mar;4(6):399-411 [9177902.001]
  • [Cites] Science. 1998 May 15;280(5366):1036-7 [9616081.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1332-9 [9782010.001]
  • [Cites] J Clin Pathol. 1999 Apr;52(4):283-90 [10474521.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):787-98 [10487836.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):153-8 [15685704.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):275-81 [15791572.001]
  • [Cites] Semin Diagn Pathol. 2004 May;21(2):134-50 [15807473.001]
  • [Cites] Oncol Rep. 2005 May;13(5):831-5 [15809746.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):69-76 [16389186.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):178-85 [10638987.001]
  • [Cites] J Clin Pathol. 2000 Apr;53(4):292-301 [10823126.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Jun;22(6):649-56 [10837360.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • (PMID = 17031402.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Carcinoembryonic Antigen; 0 / Interleukin-9; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins; 0 / Receptors, Interleukin-9; 0 / Vimentin
  • [Other-IDs] NLM/ PMC2360585
  •  go-up   go-down


100. Smeenk RM, Bex A, Verwaal VJ, Horenblas S, Zoetmulder FA: Pseudomyxoma peritonei and the urinary tract: involvement and treatment related complications. J Surg Oncol; 2006 Jan 1;93(1):20-3
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei and the urinary tract: involvement and treatment related complications.
  • BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare clinical syndrome characterized by intraperitoneal accumulation of mucus produced by neoplastic cells of mostly appendiceal origin.
  • [MeSH-major] Hyperthermia, Induced. Pelvis / surgery. Peritoneal Neoplasms / surgery. Postoperative Complications. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16353186.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement